

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau




(43) International Publication Date  
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number  
**WO 2004/012673 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number:  
PCT/US2003/024340
- (22) International Filing Date: 1 August 2003 (01.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/400,410 1 August 2002 (01.08.2002) US
- (71) Applicant (for all designated States except US): **WYETH**,  
[US/US]; Five Giralda Farms, Madison, NJ 07940 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KUAI, Jun**  
[CN/US]; 15 Farmcrest Avenue, Lexington, MA 02421  
(US). **LIN, Lih-Ling** [US/US]; 107 College Road, Con-  
cord, MA 01742 (US). **WOOTERS, Joseph, L.** [US/US];  
9 Glenley Terrace, Brighton, MA 02135 (US). **NICK-  
BARG, Elliott** [US/US]; 32 Audrey Road, Belmont, MA  
02478 (US).
- (74) Agents: **VARMA, Anita et al.**; Ropes & Gray LLP, One  
International Place, Boston, MA 02110-2624 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished  
upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND REAGENTS RELATING TO INFLAMMATION AND APOPTOSIS



(57) Abstract: The present invention relates to, among other embodiments, protein complexes which include tumor necrosis factor alpha (TNF- $\alpha$ ) and/or tumor necrosis factor alpha receptor (TNFR). Preferably, the complexes comprise at least one polypeptide selected from the group consisting of: NF- $\kappa$ B activating kinase (NAK), RasGAP3, TRCP1, and TRCP2. The present invention further provides assays of identifying a compound for modulating the stability and activity of the complex. Also provided are methods of modulating apoptosis and inflammation, as well as treating TNF- $\alpha$  related diseases.

WO 2004/012673 A2

**THIS PAGE BLANK (USPTO)**

**METHODS AND REAGENTS RELATING TO INFLAMMATION AND  
APOPTOSIS**

**Cross-Reference to Related Applications**

- 5           This application claims the benefit of priority of U.S. Provisional Application No. 60/400410, filed August 1, 2002, the specification of which is incorporated by reference herein in its entirety.

**Background**

- 10           Tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) is a pro-inflammatory cytokine produced primarily by macrophages. The pleiotropic actions of TNF- $\alpha$  include inflammation, cell proliferation, differentiation, and apoptosis (Tracey et al., (1993) Annu. Rev. Cell Biol. 9:317-313; Baud et al., (2001) Trends in Cell Biol. 11:372-377). These actions are initiated by the binding of TNF- $\alpha$  to its receptors (i.e., TNFRs) that are expressed  
15 on most kinds of cells (Baglioni et al., 1985; Beutler et al., 1985; Kull et al., 1985; Tsujimoto et al., 1985; Aggarwal et al., 1985; Israel et al., 1986). The receptors provide the intracellular signals for cell response to TNF- $\alpha$  (Engelmann et al., 1990a).

- TNF- $\alpha$  and TNFR play a role in inflammatory response. On one hand, TNF- $\alpha$  stimulates immunity, conferring resistance to infectious agents and resistance to  
20 tumors (Vilcek, et al., (1991) J. Biol. Chem. 266:7313-7316). On the other hand, TNF- $\alpha$  is implicated in a number of autoimmune diseases such as rheumatoid arthritis, graft rejection, and graft-versus-host diseases (Beutler, et al., (1998) Blood Cells Mol. Dis. 24:216-230; Beutler, (1999) J. Rheumatol. 26(Suppl) 57:16-21).

- TNF- $\alpha$  and TNFR play another role in apoptosis, or programmed cell death.  
25 Apoptosis is a physiologic process essential to the normal development and homeostasis of multicellular organisms (H. Steller, (1995) Science 267:1445-1449). Derangements of apoptosis contribute to the pathogenesis of several human diseases including cancer, neurodegenerative disorders, and acquired immune deficiency syndrome (C.B. Thompson, (1995) Science 267:1456-1462).

- 30           The effects of TNF- $\alpha$  ligands and receptors are varied and influence numerous functions, both normal and abnormal, in the biological processes of the mammalian system. There is a clear need, therefore, for identification and characterization of

protein complexes comprising such receptors and ligands, which influence biological activity, both normally and in disease states.

### Brief Summary

5 In certain aspects, the invention provides an isolated, purified, or recombinant protein complex comprising a TNF- $\alpha$  polypeptide, a TNFR polypeptide and at least one polypeptide selected from the group consisting of: NF- $\kappa$ B activating kinase (NAK), RasGAP3, TRCP1, and TRCP2. NAK is also known as TBK1 (TANK-binding kinase) or T2K (TRAF2-associated kinase). In certain embodiments, the isolated, purified, or  
10 recombinant protein complex further comprises at least one polypeptide selected from the group consisting of: TRADD, TRAF2, and TRAP2.

In certain aspects, the invention provides an isolated, purified, or recombinant protein complex comprising a TNFR polypeptide and at least one polypeptide selected from the group consisting of: NF- $\kappa$ B activating kinase (NAK), RasGAP3, TRCP1, and  
15 TRCP2. In certain embodiments, the isolated, purified, or recombinant protein complex further comprises at least one polypeptide selected from the group consisting of: TNF- $\alpha$ , TRADD, TRAF2, and TRAP2.

In a specific embodiment, the protein complex of the present invention comprises a TNF- $\alpha$  polypeptide, a TNFR polypeptide, a NAK polypeptide, a RasGAP3  
20 polypeptide, a TRCP1 polypeptide, a TRCP2 polypeptide, a TRADD polypeptide, a TRAF2 polypeptide, and a TRAP2 polypeptide. For example, the TNFR polypeptide of the complex can be a TNFR1 or TNFR2 polypeptide.

In certain embodiments, one or more of the polypeptides of a complex of the invention is a variant, such as a fragment, a fusion protein, a labeled protein, etc., and  
25 preferably the variant is a functional variant.

In further aspects, the invention provides host cells comprising one or more recombinant nucleic acids encoding one or more polypeptide constituents of a complex disclosed herein. In certain embodiments, the host cells comprise a first nucleic acid, a  
30 second nucleic acid and a third nucleic acid, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNFR polypeptide, the second nucleic acid comprises a recombinant nucleic acid encoding a TNF- $\alpha$  polypeptide, and the third nucleic acid comprises a recombinant nucleic acid encoding a polypeptide selected

from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In certain embodiments, the host cells comprise a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNFR polypeptide, and wherein the second nucleic acid comprises a recombinant nucleic acid encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

In certain aspects, the invention provides assays for identifying test compounds that inhibit or potentiate the stability of a protein complex disclosed herein. In certain embodiments, an assay comprises: forming a reaction mixture including TNF- $\alpha$ , TNFR, and at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2, and a test compound; and detecting the presence of TNF- $\alpha$  or TNFR in the complex. A change in the presence of TNF- $\alpha$  or TNFR in the complex in the presence of the test compound, relative to the presence of TNF- $\alpha$  or TNFR in the complex in the absence of the test compound, indicates that said test compound potentiates or inhibits the stability of said complex.

In certain embodiments, an assay of the invention comprises the following two steps: (i) forming a reaction mixture including TNF- $\alpha$ , TNFR, at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2, and a test compound; and (ii) detecting the association between the TNF- $\alpha$  or TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. A change in the association between TNF- $\alpha$  or TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the presence of the test compound, relative to the association between TNF- $\alpha$  or TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the absence of the test compound, indicates that said test compound potentiates or inhibits the stability of said complex. In certain embodiments, an assay of the invention comprises the following two steps: (i) forming a reaction mixture including TNFR, at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2, and a test compound; and (ii) detecting the association between the TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. Optionally, the reaction mixture may contain TNF- $\alpha$ . A change in the association between TNFR and a polypeptide selected from the group

consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the presence of the test compound, relative to the association between TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the absence of the test compound, indicates that said test compound potentiates or inhibits the stability of said complex.

In further embodiments, test compound screening assays comprise: (i) forming a protein complex comprising TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2; (ii) contacting the protein complex with a test compound; and (iii) determining the effect of the test compound for one or more activities. The protein complex may also comprise TNF- $\alpha$ . Such activities are selected from the group comprising a change in the level of the protein complex; a change in the level of the TNFR or TNF- $\alpha$  polypeptide in the complex; a change in the signaling enzymatic activity of the complex; or a change in the interaction between the TNFR or TNF- $\alpha$  polypeptide and the polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

In further embodiments, the invention provides screening assays comprising: providing a two-hybrid assay system including a first fusion protein (e.g., comprising a TNFR polypeptide portion), and a second fusion protein (e.g., comprising a portion of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2), under conditions wherein said two hybrid assay is sensitive to interactions between the first fusion protein (e.g., comprising a TNFR polypeptide) and the second fusion protein (e.g., comprising a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2); measuring a level of interactions between said fusion proteins in the presence and in the absence of a test compound; and comparing the level of interaction of said fusion proteins. A decrease in the level of interaction is indicative of a compound that will inhibit the interaction between the fusion proteins (e.g., between a TNFR polypeptide and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2). This assay of the invention can be used for any two proteins of the complex (e.g., the complex consisting of: TNF- $\alpha$ , TNFR, NAK, RasGAP3, TRCP1, and TRCP2).

In further aspects, the invention provides antibodies, or fragments thereof, specifically immunoreactive with an epitope of a polypeptide of a complex disclosed

herein, such as a polypeptide selected from the group consisting of: TNF- $\alpha$ , TNFR, NAK, RasGAP3, TRCP1, and TRCP2. Preferably the antibody disrupts formation of an interaction between TNF- $\alpha$  or TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

- 5           In certain aspects, the invention provides methods for modulating, in a cell, a protein complex comprising a first protein, a second protein and a third protein, wherein said first protein is TNF- $\alpha$ , said second protein is TNFR and said third protein is selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In certain aspects, the invention provides methods for modulating, in a cell, a protein
- 10   complex comprising a first protein and a second protein, wherein said first protein is TNF- $\alpha$  or TNFR and said second protein is selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. The method comprises administering to said cell a compound capable of modulating said protein complex.

- Further aspects of the invention relate to methods of producing a functional
- 15   complex comprising: transfecting a cell with a polynucleotide encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2; contacting said cell with a TNF- $\alpha$  or TNFR polypeptide; thereby forming a protein complex.

- A further aspect of the invention relates to methods for treating a TNF- $\alpha$ -related
- 20   disorder, by administering an effective amount of an compound that inhibits the interaction of TNF- $\alpha$  or TNFR with a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

- Other aspects of the invention relate to methods of identifying a test compound that is a candidate modulator of inflammation or apoptosis. Such methods comprise: (i)
- 25   forming a mixture comprising a TRCP1 or TRCP2 polypeptide or a variant polypeptide thereof, and a test compound; and (ii) measuring the interaction between the TRCP1 or TRCP2 polypeptide or the variant and the test compound; wherein a test compound that interacts with the TRCP1 or TRCP2 polypeptide or the functional variant thereof is a candidate modulator of inflammation or apoptosis. In such methods, the first step (i)
- 30   may comprise forming the mixture in vitro, or comprise contacting a cell expressing a TRCP1 or TRCP2 polypeptide or a variant thereof, with the test compound.

Accordingly, a further aspect of the invention relates to methods of treating a TNF- $\alpha$ -related disease which includes an inflammatory or apoptotic component, by administering an effective amount of a therapeutic composition that modulates TRCP1 or TRCP2.

5       The embodiments and practices of the present invention, other embodiments, and their features and characteristics, will be apparent from the description, figures and claims that follow, with all of the claims hereby being incorporated by this reference into this Summary.

## 10   **Brief Description Of The Drawings**

15       **Figure 1** illustrates formation of a TNF- $\alpha$  receptor complex induced by the addition of TNF- $\alpha$  ligand. **A.** Proteins in the TNF- $\alpha$  receptor complex are separated by SDS-PAGE gel and visualized by silver staining. **B.** The presence of a protein, TRADD, in the TNF- $\alpha$  receptor complex is confirmed by western blotting.

20       **Figure 2** shows the amino acid sequence (SEQ ID No: 1) of tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ).

**Figure 3** shows the cDNA sequence (SEQ ID No: 2) encoding TNF- $\alpha$ .

25       **Figure 4** shows the amino acid sequence (SEQ ID No: 3) of TNF- $\alpha$  receptor 1 (TNFR1).

**Figure 5** shows the cDNA sequence (SEQ ID No: 4) encoding TNFR1.

30       **Figure 6** shows the amino acid sequence (SEQ ID No: 5) of TNF- $\alpha$  receptor 2 (TNFR2).

**Figure 7** shows the cDNA sequence (SEQ ID No: 6) encoding TNFR2.



**Figure 8** shows the amino acid sequence (SEQ ID No: 7) of TRADD, a protein identified in the TNF- $\alpha$  receptor complex.

**Figure 9** shows the cDNA sequence (SEQ ID No: 8) encoding TRADD.

5

**Figure 10** shows the amino acid sequence (SEQ ID No: 9) of TRAF2, a protein identified in the TNF- $\alpha$  receptor complex.

**Figure 11** shows the cDNA sequence (SEQ ID No: 10) encoding TRAF2.

10

**Figure 12** shows the amino acid sequence (SEQ ID No: 11) of TRAP2, a protein identified in the TNF- $\alpha$  receptor complex.

**Figure 13** shows the cDNA sequence (SEQ ID No: 12) encoding TRAP2.

15

**Figure 14** shows the amino acid sequence (SEQ ID No: 13) of NAK (also referred to as TBK or T2K), a protein identified in the TNF- $\alpha$  receptor complex.

**Figure 15** shows the cDNA sequence (SEQ ID No: 14) encoding NAK (also referred to as TBK or T2K).

20

**Figure 16** shows the amino acid sequence (SEQ ID No: 15) of RasGAP3, a protein identified in the TNF- $\alpha$  receptor complex.

25

**Figure 17** shows the cDNA sequence (SEQ ID No: 16) encoding RasGAP3.

**Figure 18** shows the amino acid sequence (SEQ ID No: 17) of TRCP1 (also referred to as KIAA0143), a protein identified in the TNF- $\alpha$  receptor complex.

30

**Figure 19** shows the cDNA sequence (SEQ ID No: 18) encoding TRCP1 (also referred to as KIAA0143).

**Figure 20** shows the amino acid sequence (SEQ ID No: 19) of TRCP2 (similar to as FLJ20758), a protein identified in the TNF- $\alpha$  receptor complex.

**Figure 21** shows the cDNA sequence (SEQ ID No: 20) encoding TRCP2.

**Figure 22** illustrates TNF- $\alpha$  dependent recruitment of NAK, TRAF2, and TRADD on TNFR1.

### Detailed Description

#### I. Overview

Tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) is a cytokine produced primarily by lymphocytes, macrophages and several other cell types involved in a broad range of cellular responses including autoimmune responses, cell proliferation, differentiation and apoptosis. TNF- $\alpha$  belongs to a family of trimeric cytokines that bind their target receptors on the cell surface and bring about trimerization/aggregation of TNF receptors, such as TNFR1 and TNFR2 which are part of a larger TNF receptor superfamily. The interaction of TNF- $\alpha$  with its receptor(s) and the subsequent complex formation is involved in signaling responses within the cell, such responses including activation of a Caspase cascade leading to apoptosis or activation of the transcription factors AP-1 and NF- $\kappa$ B that in turn result in the transcriptional activation of genes involved in chronic and acute inflammatory responses. Also, some of the latter genes, primarily those dependent on NF- $\kappa$ B, function to suppress apoptosis in certain circumstances or cell types.

## II. Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are collected here. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

The term "binding" refers to a direct or indirect association between two molecules. Direct associations may include, for example, covalent, electrostatic, hydrophobic, ionic and/or hydrogen-bond interactions under physiological conditions. Indirect associations include, for example, two proteins that are part of a complex but do not have any direct interactions.

"Cells," "host cells" or "recombinant host cells" are terms used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A "chimeric protein" or "fusion protein" is a fusion of a first amino acid sequence encoding a polypeptide with a second amino acid sequence, wherein the first and second amino acid sequences do not occur naturally as part of a singly polypeptide chain.

The phrase "conservative amino acid substitution" refers to grouping of amino acids on the basis of certain common properties. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz, G. E. and R. H. Schirmer., Principles of Protein Structure, Springer-Verlag). According to such analyses, groups of amino acids may be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and R. H.

Schirmer., Principles of Protein Structure, Springer-Verlag). Examples of amino acid groups defined in this manner include:

- (i) a charged group, consisting of: Glu and Asp, Lys, Arg and His,
- (ii) a positively-charged group, consisting of: Lys, Arg and His,
- 5 (iii) a negatively-charged group, consisting of: Glu and Asp,
- (iv) an aromatic group, consisting of: Phe, Tyr and Trp,
- (v) a nitrogen ring group, consisting of: His and Trp,
- (vi) a large aliphatic nonpolar group, consisting of: Val, Leu and Ile,
- (vii) a slightly-polar group, consisting of: Met and Cys,
- 10 (viii) a small-residue group, consisting of: Ser, Thr, Asp, Asn, Gly, Ala, Glu, Gln and Pro,
- (ix) an aliphatic group consisting of: Val, Leu, Ile, Met and Cys, and
- (x) a small hydroxyl group consisting of: Ser and Thr.

In addition to the groups presented above, each amino acid residue may form its  
15 own group, and the group formed by an individual amino acid may be referred to simply by the one and/or three letter abbreviation for that amino acid commonly used in the art.

The terms "compound", "test compound," and "molecule" are used herein interchangeably and are meant to include, but are not limited to, peptides, nucleic acids,  
20 carbohydrates, small organic molecules, natural product extract libraries, and any other molecules (including, but not limited to, chemicals, metals, and organometallic compounds).

A "conserved residue" is an amino acid that is relatively invariant across a range of similar proteins. Often conserved residues will vary only by being replaced  
25 with a similar amino acid, as described above for "conservative amino acid substitution."

The term "domain" as used herein refers to a region of a protein that comprises a particular structure and/or performs a particular function.

"Homology" or "identity" or "similarity" refers to sequence similarity between  
30 two peptides or between two nucleic acid molecules. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When an equivalent position in the compared sequences is

occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of

5 homology/similarity or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. A sequence which is "unrelated" or "non-homologous" shares less than 40% identity, preferably less than 25% identity with a sequence of the present invention. In comparing two sequences, the absence of residues (amino acids or nucleic acids) or presence of extra residues also

10 decreases the identity and homology/similarity.

The term "homology" describes a mathematically based comparison of sequence similarities which is used to identify genes or proteins with similar functions or motifs. The nucleic acid and protein sequences of the present invention may be used as a "query sequence" to perform a search against public databases to, for example,

15 identify other family members, related sequences or homologs. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to nucleic acid molecules of the invention. BLAST protein searches can

20 be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g.,

25 XBLAST and BLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

As used herein, "identity" means the percentage of identical nucleotide or amino acid residues at corresponding positions in two or more sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions. Identity can be readily calculated by known methods, including but not

30 limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of

Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, S. F. et al., J. Molec. Biol. 215: 403-410 (1990) and Altschul et al. Nuc. Acids Res. 25: 3389-3402 (1997)). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990)). The well known Smith Waterman algorithm may also be used to determine identity.

The term "including" is used herein to mean, and is used interchangeably with, the phrase "including but not limited to".

The term "isolated", as used herein with reference to the subject proteins and protein complexes, refers to a preparation of protein or protein complex that is essentially free from contaminating proteins that normally would be present with the protein or complex, e.g., in the cellular milieu in which the protein or complex is found endogenously. Thus, an isolated protein complex is isolated from cellular components that normally would "contaminate" or interfere with the study of the complex in isolation, for instance while screening for modulators thereof. It is to be understood, however, that such an "isolated" complex may incorporate other proteins the modulation of which, by the subject protein or protein complex, is being investigated.

The term "isolated" as also used herein with respect to nucleic acids, such as DNA or RNA, refers to molecules in a form which does not occur in nature. Moreover, an "isolated nucleic acid" is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state.

As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The

term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides.

5       The term "or" is used herein to mean, and is used interchangeably with, the term "and/or", unless context clearly indicates otherwise.

      The terms "proteins," and "polypeptides" are used interchangeably herein.

      The term "purified protein" refers to a preparation of a protein or proteins which are preferably isolated from, or otherwise substantially free of, other proteins normally associated with the protein(s) in a cell or cell lysate. The term "substantially free of  
10       other cellular proteins" (also referred to herein as "substantially free of other contaminating proteins") is defined as encompassing individual preparations of each of the component proteins comprising less than 20% (by dry weight) contaminating protein, and preferably comprises less than 5% contaminating protein. Functional  
15       forms of each of the component proteins can be prepared as purified preparations by using a cloned gene as described in the attached examples. By "purified", it is meant, when referring to component protein preparations used to generate a reconstituted protein mixture, that the indicated molecule is present in the substantial absence of other biological macromolecules, such as other proteins (particularly other proteins  
20       which may substantially mask, diminish, confuse or alter the characteristics of the component proteins either as purified preparations or in their function in the subject reconstituted mixture). The term "purified" as used herein preferably means at least 80% by dry weight, more preferably in the range of 85% by weight, more preferably 95-99% by weight, and most preferably at least 99.8% by weight, of biological  
25       macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 5000, can be present). The term "pure" as used herein preferably has the same numerical limits as "purified" immediately above.

      The term "recombinant nucleic acid" includes any nucleic acid comprising at  
30       least two sequences which are not present together in nature. A recombinant nucleic acid may be generated in vitro, for example by using the methods of molecular biology,

or in vivo, for example by insertion of a nucleic acid at a novel chromosomal location by homologous or non-homologous recombination.

The term "recombinant protein" refers to a protein of the present invention which is produced by recombinant DNA techniques, wherein generally DNA encoding the expressed protein is inserted into a suitable expression vector which is in turn used to transform a host cell to produce the heterologous protein. Moreover, the phrase "derived from", with respect to a recombinant gene encoding the recombinant protein is meant to include within the meaning of "recombinant protein" those proteins having an amino acid sequence of a native protein, or an amino acid sequence similar thereto which is generated by mutations including substitutions and deletions of a naturally occurring protein.

"Small molecule" as used herein, is meant to refer to a composition, which has a molecular weight of less than about 5 kD and most preferably less than about 2.5 kD. Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic (carbon containing) or inorganic molecules. Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures comprising arrays of small molecules, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the invention.

As used herein, the term "specifically hybridizes" refers to the ability of a nucleic acid probe/primer of the invention to hybridize to at least 12, 15, 20, 25, 30, 35, 40, 45, 50 or 100 consecutive nucleotides of a target sequence, or a sequence complementary thereto, or naturally occurring mutants thereof, such that it has less than 15%, preferably less than 10%, and more preferably less than 5% background hybridization to a cellular nucleic acid (e.g., mRNA or genomic DNA) other than the target gene. A variety of hybridization conditions may be used to detect specific hybridization, and the stringency is determined primarily by the wash stage of the hybridization assay. Generally high temperatures and low salt concentrations give high stringency, while low temperatures and high salt concentrations give low stringency. Low stringency hybridization is achieved by washing in, for example, about 2.0 x SSC at 50 °C, and high stringency is achieved with about 0.2 x SSC at 50 °C. Further descriptions of stringency are provided below.



As applied to polypeptides, "substantial sequence identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap which share at least 90 percent sequence identity, preferably at least 95 percent sequence identity, more preferably at least 99 percent sequence identity or  
5 more. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. For example, the substitution of amino acids having similar chemical properties such as charge or polarity are not likely to effect the properties of a protein. Examples include glutamine for asparagine or glutamic acid for aspartic acid.

The term "tumor necrosis factor alpha receptor" or "TNFR" includes TNFR1,  
10 TNFR2, and functional fragments and analogs thereof. The term TNFR also includes any polypeptide that binds to TNF- $\alpha$  and transduces such binding so as to affect an intracellular signaling pathway.

A "variant" of a polypeptide, such as, for example, a variant of a TNF- $\alpha$ , a TNFR, a TRCP1 or a TRCP2 includes chimeric proteins, fusion proteins, mutant  
15 proteins, proteins having similar but non-identical sequences, protein fragments, mimetics, etc, so long as the variant has at least a portion of an amino acid sequence of a native protein, or at least a portion of an amino acid sequence of substantial sequence identity to the native protein. A "functional variant" includes a variant that retains at least one function of the native protein. As used herein, the term "tumor necrosis factor  
20 alpha" or "TNF- $\alpha$ " includes functional variants of TNF- $\alpha$ .

### III. Protein Complexes

In certain embodiments, the present invention relates to the discovery of novel protein complexes. In certain embodiments, protein complexes of the invention  
25 comprise a TNF- $\alpha$  polypeptide, a TNFR polypeptide and at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. Optionally, such protein complexes further comprise at least one polypeptide selected from the group consisting of: TRADD, TRAF2, and TRAP2 or a polypeptide known to form a complex with TNF- $\alpha$  or TNFR, such as TRAF1, RIP, RAIDD, or FADD.

30 In a specific embodiment, protein complexes of the invention comprise polypeptides of TNF- $\alpha$ , TNFR1, NAK, TRAF2, and TRADD.

In another specific embodiment, the protein complex of the present invention comprises a TNF- $\alpha$  polypeptide, a TNFR polypeptide, a NAK polypeptide, a RasGAP3 polypeptide, a TRCP1 polypeptide, a TRCP2 polypeptide, a TRADD polypeptide, a TRAF2 polypeptide, and a TRAP2 polypeptide. For example, the TNFR polypeptide  
5 of the complex can be a TNFR1 or TNFR2 polypeptide.

In further embodiments, protein complexes of the invention comprise a TNFR and at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. Optionally, such protein complexes further comprise at least one polypeptide selected from the group consisting of: TRADD, TRAF2, and TRAP2 or a  
10 polypeptide known to form a complex with TNFR, such as TRAF1, RIP, RAIDD, or FADD.

The present invention also contemplates protein complexes comprising any two polypeptides selected from the group consisting of: TNF- $\alpha$ , TNFR, NAK, RasGAP3, TRCP1, and TRCP2. Optionally, such protein complexes further comprise at least one  
15 polypeptide selected from the group consisting of: TRADD, TRAF2, and TRAP2 or a polypeptide known to form a complex with TNFR, such as TRAF1, RIP, RAIDD, or FADD.

Optionally, one or more of the polypeptides of a complex is a variant of that polypeptide, and preferably a functional variant of that polypeptide. For example, in  
20 one embodiment, protein complexes of the invention comprise TNF- $\alpha$  and NAK wherein either TNF- $\alpha$  and/or NAK may be represented by a variant of TNF- $\alpha$  and/or NAK.

Complexes of the invention may be obtained in essential form, such as, for example, as an isolated complex, a recombinant complex, a purified complex, etc. In  
25 an embodiment, the invention provides a protein complex prepared, for example, by extraction from a cell that comprises the complex. Extraction from a cell may be accomplished by any of the many methods known in the art. For example, a complex may be extracted from the cell by a series of traditional protein purification steps, such as centrifugation, gel filtration, ion exchange chromatography, etc., and it will generally  
30 be preferable to select purification steps and conditions that do not dissociate the complex. Extraction from a cell may also be achieved by affinity purification. For example, one or more of the proteins in the desired complex may be expressed as a

fusion protein comprising an affinity purification tag, such as a hexahistidine tag, a glutathione-S-transferase (GST) tag, etc. The complex may then be purified by an appropriate affinity purification (e.g., contacting with a nickel or copper resin in the case of a hexahistidine tag, contacting with a glutathione resin in the case of a GST tag.

- 5 In another preferred form, the invention provides a protein complex, for example, prepared by purifying recombinant polypeptides expressed in cells such as *E. coli* and reconstituting the complex in vitro. In certain embodiments, one or more of the constituent polypeptides of a complex is expressed from an endogenous gene of a cell. In certain embodiments, complexes are recombinant complexes wherein one or more of
- 10 the constituent polypeptides is expressed from a recombinant nucleic acid.

- In certain embodiments, the invention also includes labeled protein complexes, wherein at least one polypeptide of the complex is labeled. Most preferably, the label is a detectable label, selected from, but not limited to, the group consisting of: radioisotopes, fluorescent compounds, enzymes, and enzyme co-factors. In another
- 15 embodiment, the label is a label that facilitates purification, isolation, or detection of the polypeptide. The label may be a polyhistidine, FLAG, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, and an immunoglobulin heavy chain constant region. In a preferred embodiment, the labeled protein is TNF- $\alpha$ . In another preferred embodiment, the labeled protein is TNFR.

- 20 In an embodiment, the present invention contemplates protein complexes comprising fusion protein(s), wherein said fusion protein comprises a domain that facilitates purification, isolation, or detection of said fusion protein. The fusion domain may be selected from, for example, the group consisting of: polyhistidine, FLAG, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, and an
- 25 immunoglobulin heavy chain constant region. A preferred fusion domain is FLAG. In certain embodiments, the complex comprises a TNF- $\alpha$  fusion protein. In certain embodiments, the complex comprises a TNFR fusion protein. In certain embodiments, the complex comprises a TNF- $\alpha$  fusion protein and a TNFR fusion protein

- As noted above, in certain embodiments, protein complexes of the present
- 30 invention comprise at least one fragment of any polypeptide component in the complex. In certain embodiments, the complex comprises a fragment of a TNF- $\alpha$  polypeptide, a full-length TNFR polypeptide, and a full-length polypeptide selected from the group

consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In certain embodiments, the complex comprises a fragment of a TNF- $\alpha$  polypeptide, a fragment of a TNFR polypeptide, and a full-length polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In certain embodiments, the complex comprises a full-length TNF- $\alpha$  polypeptide, a fragment of a TNFR polypeptide, and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In certain embodiments, the complex comprises a full-length TNF- $\alpha$  polypeptide, a full-length TNFR polypeptide, and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In certain embodiments, the complex comprises a fragment of TNF- $\alpha$  polypeptide, a full-length of a TNFR polypeptide, and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In certain embodiments, the complex comprises a fragment of TNF- $\alpha$  polypeptide, a fragment of a TNFR polypeptide, and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

In preferred embodiments, a fragment of any of the preceding polypeptides is a functional fragment that, for example, retains the ability to associate with at least one other polypeptide of the complex. An example of a functional fragment of a TNFR1 is a fragment that encompasses an intracellular death domain (DD) of TNFR1, approximately 80 amino acids towards the carboxyl-end of TNFR1. An additional example of a functional fragment is a fragment that encompasses a Serine/Threonine protein kinase catalytic domain (S\_TKc) of NAK, approximately 235 amino acids at the amino-end of NAK. In certain embodiments, a fragment in the complex encompasses a domain of RasGAP3 selected from the group consisting of: 1) a protein kinase C conserved region 2 domain (C2), approximately 100 amino acids at the amino-terminus; 2) a RasGAP domain, approximately 320 amino acids in the center region; 3) a pleckstrin homology domain (PH), approximately 100 amino acids towards the carboxyl-end; 4) a BTK domain, approximately 35 amino acids towards the carboxyl-end.

In certain embodiment, a complex of the invention is in the water-soluble form (a "soluble complex"). For example, a soluble may comprise a soluble cytoplasmic portion of a TNFR and at least one polypeptide selected from the group consisting of:

NAK, RasGAP3, TRCP1, and TRCP2. Optionally, such protein complexes further comprise at least one polypeptide selected from the group consisting of: TRADD, TRAF2, and TRAP2 or a protein known to form a complex with TNFR, such as TRAF1, RIP, RAIDD, or FADD. In certain embodiments, the complex is in a water-insoluble or membrane-associated form. For example, a complex comprising a protein having a transmembrane domain (such as a full-length TNFR) will generally be water-insoluble. Insoluble complexes may be prepared, for example, as lipid micelles, detergent micelles or mixed micelles comprising lipids, detergents and/or other components. Insoluble complexes may also be prepared as membrane fractions from a cell. A membrane fraction may be a crude membrane fraction, wherein the membrane portion is simply separated from the soluble portion of a cell by, for example, centrifugation or filtration. A membrane fraction may be further purified by, for example, affinity purification directed to an affinity tag present in one or more of the proteins of a complex. Where a complex is present in a lipid bilayer, the lipid bilayer may, for example, be a vesicle (optionally inverted, i.e., with the normally extracellular face facing inwards towards the interior of the vesicle) or a planar bilayer. In embodiments where a complexes comprises a TNFR, the TNFR is preferably TNFR1 or a variant thereof (e.g., a soluble cytoplasmic portion, a DD domain, etc.).

In certain embodiments, the present invention also provides additional methods of producing a functional protein complex. In a preferred embodiment, such methods comprise (i) transfecting a cell with a polynucleotide encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2; (ii) contacting said cell with TNF- $\alpha$  polypeptide; (iii) thereby forming a protein complex.

#### IV. Polypeptides of protein complexes

In certain aspects, complexes of the invention comprise polypeptides selected from the group consisting of: TNF- $\alpha$ , TNFR, NAK, RasGAP3, TRCP1, TRCP2, TRADD, TRAF2, and TRAP2, and additional components described herein, and variants polypeptides thereof. In certain embodiments, variant polypeptides have an amino acid sequence that is at least 75% identical to an amino acid sequence as set forth in any of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19. In other embodiments, the variant polypeptide has an amino acid sequence at least 80%, 85%, 90%, 95%,

97%, 98%, 99% or 100% identical to an amino acid sequence as set forth in any of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19. Preferred polypeptides of the complex are the native human NAK, RasGAP3, TRCP1, and TRCP2 sequences (SEQ ID Nos: 13, 15, 17, and 19).

5 In certain aspects, protein complexes comprise variant polypeptides that are agonists or antagonists of polypeptides as set forth in any of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19. Variants of these polypeptides may have a hyperactive or constitutive activity, or, alternatively, act to prevent TNF- $\alpha$ -dependent formation of the protein complex. For example, a truncated form lacking one or more domain may have  
10 a dominant negative effect.

In certain aspects, protein complexes comprise variant polypeptides derived from a full-length polypeptides as set forth in any of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19. Isolated peptidyl portions of these polypeptides can be obtained by screening polypeptides recombinantly produced from the corresponding fragment of  
15 the nucleic acid (encoding such polypeptides) as set forth in any of SEQ ID Nos: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, any one of the subject proteins can be arbitrarily divided into fragments of desired length with no overlap of the fragments, or preferably  
20 divided into overlapping fragments of a desired length. The fragments can be produced (recombinantly or by chemical synthesis) and tested to identify those peptidyl fragments which can function as either agonists or antagonists of the formation of a TNFR protein complex.

In certain aspects, protein complexes comprise variant polypeptides containing  
25 one or more fusion domain(s). Well known examples of such fusion domains include, for example, polyhistidine, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, and an immunoglobulin heavy chain constant region (Fc), maltose binding protein (MBP), which are particularly useful for isolation of the fusion polypeptide by affinity chromatography. For the purpose of affinity purification,  
30 relevant matrices for affinity chromatography, such as glutathione-, amylase-, and nickel- or cobalt- conjugated resins are used. Many of such matrices are available in

“kit” form, such as the Pharmacia GST purification system and the QIAexpress™ system (Qiagen) useful with (HIS<sub>6</sub>) fusion partners.

Another fusion domain well known in the art is green fluorescent protein (GFP). This fusion partner serves as a fluorescent “tag” which allows the fusion polypeptide of the invention to be identified by fluorescence microscopy or by flow cytometry. The GFP tag is useful when assessing subcellular localization of the fusion polypeptide of the invention, or assessing the co-localization of at least two polypeptides of the protein complex of which one polypeptide is fused with GFP. The GFP tag is also useful for isolating cells which express the fusion polypeptide of the invention by flow cytometric methods such as a fluorescence activated cell sorting (FACS).

Fusion domains also include “epitope tags,” which are usually short peptide sequences for which a specific antibody is available. Well known epitope tags for which specific monoclonal antibodies are readily available include FLAG, influenza virus haemagglutinin (HA), and c-myc tags.

In some cases, the fusion domains have a protease cleavage site, such as for Factor Xa or Thrombin, which allow the relevant protease to partially digest the fusion polypeptide of the invention and thereby liberate the recombinant polypeptide therefrom. The liberated polypeptide can then be isolated from the fusion partner by subsequent chromatographic separation.

In certain embodiment, recombinant proteins of the complex may be conveniently prepared by a person skilled in the art using standard protocols as for example described in Sambrook, *et al.*, Molecular Cloning. A Laboratory Manual (Cold Spring Harbor Press, 1989); Current Protocols In Molecular Biology Eds. Ausubel *et al.*; and Current Protocols In Protein Science Eds. Coligan *et al.*.

In certain embodiments, variants of polypeptides of a complex may be generated by making one or more conservative substitution in a native polypeptide sequence. For instance, it is reasonable to expect, for example, that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (i.e., conservative mutations) will not have a major effect on the biological activity of the resulting molecule. Conservative replacements are those that take place within a family of amino acids that are related in their side chains.

Genetically encoded amino acids are can be divided into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) nonpolar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine.

5 Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In similar fashion, the amino acid repertoire can be grouped as (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine histidine, (3) aliphatic = glycine, alanine, valine, leucine, isoleucine, serine, threonine, with serine and threonine optionally be grouped separately as aliphatic-hydroxyl; (4) aromatic = phenylalanine, 10 tyrosine, tryptophan; (5) amide = asparagine, glutamine; and (6) sulfur -containing = cysteine and methionine (see, for example, Biochemistry, 2nd ed., Ed. by L. Stryer, W.H. Freeman and Co., 1981). Whether a change in the amino acid sequence of a polypeptide results in a functional homolog can be readily determined by assessing the ability of the variant polypeptide to produce a response in cells in a fashion similar to 15 the wild-type protein. For instance, such variant forms of polypeptides as set forth in any of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, can be assessed, e.g., for their ability to bind to another polypeptide in the protein complex. Polypeptides in which more than one replacement has taken place can readily be tested in the same manner.

In certain embodiment, the invention further contemplates a method of 20 generating sets of combinatorial mutants of the subject polypeptides, as well as truncation mutants, and is especially useful for identifying potential variant sequences (e.g., homologs) that are functional in forming the protein complex of the invention. The purpose of screening such combinatorial libraries is to generate, for example, homologs which can act as either agonists or antagonist, or alternatively, which possess 25 novel activities all together. Combinatorially-derived homologs can be generated which have a selective potency relative to a naturally occurring polypeptide. Such proteins, when expressed from recombinant DNA constructs, can be used in the assay protocols described herein. In similar fashion, homologs of the subject polypeptides as set forth in any of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19, can be generated by 30 the present combinatorial approach to act as antagonists, in that they are able to interfere with the ability of the corresponding wild-type protein to function in the protein complex of the invention.



Other forms of mutagenesis can be utilized to generate a combinatorial library. For example, homologs of the subject proteins (both agonist and antagonist forms) can be generated and isolated from a library by screening using, for example, alanine scanning mutagenesis and the like (Ruf et al., (1994) *Biochemistry* 33:1565-1572; Wang et al., (1994) *J. Biol. Chem.* 269:3095-3099; Balint et al., (1993) *Gene* 137:109-118; Grodberg et al., (1993) *Eur. J. Biochem.* 218:597-601; Nagashima et al., (1993) *J. Biol. Chem.* 268:2888-2892; Lowman et al., (1991) *Biochemistry* 30:10832-10838; and Cunningham et al., (1989) *Science* 244:1081-1085), by linker scanning mutagenesis (Gustin et al., (1993) *Virology* 193:653-660; Brown et al., (1992) *Mol. Cell Biol.* 12:2644-2652; McKnight et al., (1982) *Science* 232:316); by saturation mutagenesis (Meyers et al., (1986) *Science* 232:613); by PCR mutagenesis (Leung et al., (1989) *Method Cell Mol. Biol.* 1:11-19); or by random mutagenesis, including chemical mutagenesis, etc. (Miller et al., (1992) *A Short Course in Bacterial Genetics*, CSHL Press, Cold Spring Harbor, NY; and Greener et al., (1994) *Strategies in Mol. Biol.* 7:32-34). Linker scanning mutagenesis, particularly in a combinatorial setting, is an attractive method for identifying truncated (bioactive) forms of the subject proteins.

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations and truncations, and, for screening cDNA libraries for gene products having a certain property. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of homologs of the subject proteins. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected.

In certain embodiment, the invention also provides for reduction of polypeptides to generate variants that are mimetics, e.g., peptide or non-peptide compounds, which are able to mimic binding of the authentic protein to another cellular partner. Such mutagenic techniques as described above are also particularly useful for mapping the determinants of a polypeptide which participate in protein-protein interactions involved in, for example, the assembly of protein complexes of the

invention. To illustrate, the critical residues of a polypeptide (such as NAK), which are involved in molecular recognition of an interactive protein (such as TNFR or TNF- $\alpha$ ) can be determined and used to generate NAK polypeptide-derived peptidomimetics which bind to TNFR, and by inhibiting NAK binding, act to inhibit the assembly or signaling activity of the protein complex. By employing, for example, scanning mutagenesis to map the amino acid residues of a polypeptide which are involved in binding to another polypeptide, peptidomimetic compounds can be generated which mimic those residues involved in binding. For instance, non-hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (e.g., see Freidinger et al., in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al., in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al., in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al., (1986) *J. Med. Chem.* 29:295; and Ewenson et al., in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), b-turn dipeptide cores (Nagai et al., (1985) *Tetrahedron Lett.* 26:647; and Sato et al., (1986) *J. Chem. Soc. Perkin Trans.* 1:1231), and b-aminoalcohols (Gordon et al., (1985) *Biochem Biophys Res. Commun.* 126:419; and Dann et al., (1986) *Biochem Biophys Res. Commun.* 134:71).

#### V. Nucleic Acids

In certain aspects, complexes of the invention comprise polypeptides encoded by nucleic acids selected from the group consisting of: TNF- $\alpha$ , TNFR, NAK, RasGAP3, TRCP1, TRCP2, TRADD, TRAF2, TRAP2, and additional components described herein. Nucleic acids are further understood to include nucleic acids that comprise variants of SEQ ID Nos: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20. Variant nucleotide sequences include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants; and will, therefore, include coding sequences that differ from the nucleotide sequence of the coding sequence e.g., due to the degeneracy of the genetic code. In certain embodiments, variant nucleic acids will also include sequences that will hybridize under highly stringent conditions

to a nucleotide sequence of a coding sequence designated in any of SEQ ID Nos: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20. One of ordinary skill in the art will understand readily that appropriate stringency conditions which promote DNA hybridization can be varied. For example, one could perform the hybridization at 6.0 x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0 x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50 °C to a high stringency of about 0.2 x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6 x SSC at room temperature followed by a wash at 2 x SSC at room temperature.

Isolated nucleic acids which differ from SEQ ID Nos: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 due to degeneracy in the genetic code are also within the scope of the invention. For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" mutations which do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the subject proteins will exist among mammalian cells. One skilled in the art will appreciate that these variations in one or more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding a particular protein may exist among individuals of a given species due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymorphisms are within the scope of this invention.

#### VI. Host Cells

In one embodiment, the invention provides host cells comprising at least three nucleic acids encoding any three polypeptides of a protein complex of the invention or variants thereof. In one embodiment, the first nucleic acid comprises a recombinant nucleic acid encoding a TNF- $\alpha$  polypeptide, wherein the second nucleic acid comprises a recombinant nucleic acid encoding a TNFR polypeptide and wherein the third nucleic

acid comprises a recombinant nucleic acid encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In one embodiment, the second nucleic acid encodes a TNFR1 polypeptide. In another embodiment, the second nucleic acid encodes a TNFR2 polypeptide. In one embodiment, the third nucleic acid  
5 encodes a NAK polypeptide. In another embodiment, the third nucleic acid encodes a RasGAP3 polypeptide. In another embodiment, the third nucleic acid encodes TRCP1 polypeptide. In another embodiment, the third nucleic acid encodes TRCP2 polypeptide.

In certain aspects, the invention provides host cells comprising at least two  
10 recombinant nucleic acids encoding any two polypeptides of a protein complex of the invention or variants thereof. In one embodiment, the first nucleic acid comprises a recombinant nucleic acid encoding a TNFR polypeptide, and wherein the second nucleic acid comprises a recombinant nucleic acid encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. In one  
15 embodiment, the first nucleic acid encodes a TNFR1 polypeptide. In another embodiment, the first nucleic acid encodes a TNFR2 polypeptide. In one embodiment, the second nucleic acid encodes a NAK polypeptide. In another embodiment, the second nucleic acid encodes a RasGAP3 polypeptide. In another embodiment, the second nucleic acid encodes TRCP1 polypeptide. In another embodiment, the second  
20 nucleic acid encodes TRCP2 polypeptide.

In further aspects, the invention provides host cells comprising a recombinant nucleic acid encoding TRCP1, TRCP2 or a variant thereof. In some embodiments, host cells may be used, for example, for purifying, making or studying a protein or protein complex. Optionally, host cells may be used, for example, for testing compounds in  
25 assay protocols such as those described below.

In certain embodiments, recombinant expression of polypeptides of a complex of the invention may be performed separately, and complexes formed therefrom. In another embodiment, recombinant expression of such polypeptides of a complex of the invention may be performed in the same cell, and complexes formed therefrom.

30 Suitable host cells for recombinant expression include bacteria such as *E. coli.*, *Clostridium* sp., *Pseudomonas* sp., yeast, plant cells, insect cells (such as *Sf9*) and

mammalian cells such as fibroblasts, lymphocytes, U937 cells (or other promonocytic cell lines) and Chinese hamster ovary cells (CHO cells).

For the purpose of host cell expression, the recombinant nucleic acid may be operably linked to one or more regulatory sequences in an expression construct.

5 Regulatory nucleotide sequences will generally be appropriate for the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and  
10 termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the invention. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an episome, such as a plasmid, or the  
15 expression construct may be inserted in a chromosome. In a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

The expression vector may also include a fusion domain (typically provided by  
20 the expression vector) so that the recombinant polypeptide of the invention is expressed as a fusion polypeptide with said fusion domain. The main advantage of fusion domains are that they assist identification and/or purification of said fusion polypeptide and also enhance protein expression level and overall yield.

## 25 VII. Antibodies and Uses Therefor

Another aspect of the invention pertains to an isolated antibody specifically immunoreactive with an epitope of a polypeptide selected from the group consisting of: TNF- $\alpha$ , TNFR, NAK, RasGAP3, TRCP1, and TRCP2, TRADD, TRAF2, and TRAP2 or a protein known to form a complex with TNF- $\alpha$ , such as TRAF1, RIP, RAIDD, or  
30 FADD, wherein said antibody disrupts formation of a complex of the invention. By using immunogens derived from an NAK polypeptide (e.g., based on the cDNA sequences), anti-protein/anti-peptide antisera or monoclonal antibodies can be made by

standard protocols (see, for example, Antibodies: A Laboratory Manual ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)).

In one embodiment, antibodies of the invention disrupt the formation of an interaction between TNF- $\alpha$  and NAK. In another embodiment, antibodies of the invention disrupt the formation of an interaction between TNF- $\alpha$  and RasGAP3. In another embodiment, antibodies of the invention disrupt the formation of an interaction between TNF- $\alpha$  and TRCP1. In another embodiment, antibodies of the invention disrupt the formation of an interaction between TNF- $\alpha$  and TRCP2.

In one embodiment, the antibody of the invention is a monoclonal antibody. In another embodiment, the antibody of the invention is a Fab fragment. In one embodiment, the antibody of the invention is labeled with a detectable label.

A mammal, such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide (e.g., an NAK polypeptide or an antigenic fragment which is capable of eliciting an antibody response, or a fusion protein as described above). Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of a polypeptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies. In a preferred embodiment, the subject antibodies are immunospecific for antigenic determinants of polypeptides set forth in SEQ ID NO:14, 16, 18, and 20.

The present invention contemplates antibodies that are specific for a death domain (DD), and preferably the DD domain is part of a TNFR polypeptide. In a more specific embodiment, the DD domain is the region of approximately 80 amino acids in length towards the carboxyl-end of the TNFR1 as set forth in SEQ ID NO: 3.

Following immunization of an animal with an antigenic preparation of the subject polypeptides, antisera can be obtained and, if desired, polyclonal antibodies isolated from the serum. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Such techniques are well known in the art, and include, for example,

the hybridoma technique (originally developed by Kohler and Milstein, (1975) Nature, 256: 495-497), the human B cell hybridoma technique (Kozbar et al., (1983) Immunology Today, 4: 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., (1985) Monoclonal Antibodies and Cancer

5 Therapy, Alan R. Liss, Inc. pp. 77-96). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with polypeptides of the present invention and monoclonal antibodies isolated from a culture comprising such hybridoma cells. In one embodiment, an anti-NAK antibody specifically reacts with the protein encoded by a nucleic acid having SEQ ID NO:14.

10 The term antibody as used herein is intended to include fragments thereof which are also specifically reactive with one of the subject polypeptides. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)<sub>2</sub> fragments can be generated by treating antibody with pepsin. The resulting F(ab)<sub>2</sub> fragment can  
15 be treated to reduce disulfide bridges to produce Fab fragments.

The antibody of the present invention is further intended to include bispecific, single-chain, and chimeric and humanized molecules having affinity for one of the subject polypeptides, conferred by at least one CDR region of the antibody. In preferred embodiments, the antibody further comprises a label attached thereto and able  
20 to be detected (e.g., the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor).

#### VIII. Drug Screening Assays

In certain embodiments, the present invention provides assays for identifying  
25 test compounds which either inhibit or potentiate the stability of the protein complex of the invention. In one aspect, the assays detect test compounds which inhibit or potentiate interaction of one polypeptide with another polypeptide in the protein complex of the invention.

In certain embodiments, the assays detect test compounds which modulate the  
30 signaling activities of the protein complex, such as binding to other cellular components, activating enzymes such as caspases, lipases, kinases, and phosphatases, activating NF- $\kappa$ B transcriptional activity, and the like.

A variety of assay formats will suffice and, in light of the present disclosure, those not expressly described herein will nevertheless be comprehended by one of ordinary skill in the art. Assay formats which approximate such conditions as formation of protein complexes, enzymatic activity, and may be generated in many different forms, and include assays based on cell-free systems, e.g., purified proteins or cell lysates, as well as cell-based assays which utilize intact cells. Simple binding assays can be used to detect compounds that inhibit or potentiate the interaction between one polypeptide and another polypeptide in the complex, or the binding of the complex to a substrate. Compounds to be tested can be produced, for example, by bacteria, yeast or other organisms (e.g., natural products), produced chemically (e.g., small molecules, including peptidomimetics), or produced recombinantly.

In many embodiments, a cell is manipulated after incubation with a candidate compound and assayed for activities of the protein complex of invention. In certain embodiments, bioassays for activities of a protein complex may include apoptosis assays (e.g., caspase and TUNEL assays) and NF-kB activity assays (e.g., NF-kB luciferase or GFP reporter gene assays).

Exemplary apoptosis assays (e.g., caspase and TUNEL assays) may be carried out as described by Chaisson et al., (2002) J. Clin. Invest. 110:193-202. Cells are incubated with a candidate compound or left untreated. Cell lysates are then incubated with a fluorogenic caspase-3 substrate, DEVD-AMC (Alexis Corp., San Diego, California, USA), for 1 hour. Fluorescence is quantitated using a fluorescent plate reader (Packard Instrument Co., Meriden, Connecticut, USA) at an excitation wavelength of 360 nm and an emission wavelength of 460 nm. For the TUNEL assay, apoptotic nuclei are detected using the POD In Situ Cell Death Detection kit (Roche Diagnostics Inc.) according to the manufacturer's instructions. Positive nuclei were counted in 30 fields (x400) for each slide.

Exemplary NF-kB luciferase or GFP reporter gene assays may be carried out as described by Shona et al., (2002) FEBS Letters. 515: 119-126. Briefly, cells are transfected with an NF-kB-luciferase reporter gene. The transfected cells are then incubated with a candidate compound. Subsequently, NF-kB-stimulated luciferase activity is measured in cells treated with the compound or without the compound. Alternatively, cells can be transfected with an NF-kB-GFP reporter gene (Stratagene).



The transfected cells are then incubated with a candidate compound. Subsequently, NF-kB-stimulated gene activity is monitored by measuring GFP expression with a fluorescence/visible light microscope set-up or by FACS analysis.

In certain embodiments, the present invention provides reconstituted protein  
5 preparations including a polypeptide of the complex, and one or more interacting polypeptides of the complex. Assays of the present invention include labeled in vitro protein-protein binding assays, immunoassays for protein binding, and the like. The purified protein may also be used for determination of three-dimensional crystal structure, which can be used for modeling intermolecular interactions.

10 In certain embodiments of the present assays, component polypeptides of the complex can be endogenous to the cell selected to support the assays. Alternatively, some or all of the component polypeptides can be derived from exogenous sources. For instance, fusion proteins can be introduced into the cell by recombinant techniques (such as through the use of an expression vector), as well as by microinjecting the  
15 fusion protein itself or mRNA encoding the fusion protein.

In further embodiments of the assays, a complex can be generated in whole cells, taking advantage of cell culture techniques to support the subject assays. For example, as described below, a complex can be constituted in a eukaryotic cell culture system, including mammalian and yeast cells. Advantages to generating the subject  
20 assays in an intact cell include the ability to detect compounds which are functional in an environment more closely approximating that which therapeutic use of the compounds would require, including the ability of the compound to gain entry into the cell. Furthermore, certain of the in vivo embodiments of the assay, such as examples given below, are amenable to high through-put analysis of candidate compounds.

25 In certain in vitro embodiments of the present assay, a reconstituted complex comprises a reconstituted mixture of at least semi-purified proteins. By semi-purified, it is meant that the proteins utilized in the reconstituted mixture have been previously separated from other cellular proteins. For instance, in contrast to cell lysates, proteins involved in the complex formation are present in the mixture to at least 50% purity  
30 relative to all other proteins in the mixture, and more preferably are present at 90-95% purity. In certain embodiments of the subject method, the reconstituted protein mixture is derived by mixing highly purified proteins such that the reconstituted mixture

substantially lacks other proteins (such as of cellular origin) which might interfere with or otherwise alter the ability to measure the complex assembly and/or disassembly.

In certain embodiments, assaying in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants.

5 Examples include microtitre plates, test tubes, and micro-centrifuge tubes.

In certain embodiments, drug screening assays can be generated which detect test compounds on the basis of their ability to interfere with assembly, stability, or function of a complex of the invention. In an exemplary binding assay, the compound of interest is contacted with a mixture comprising a TNF- $\alpha$  polypeptide, a TNFR  
10 polypeptide and at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2. Detection and quantification of the complex provide a means for determining the compound's efficacy at inhibiting (or potentiating) interaction between the two component polypeptides. The efficacy of the compound can be assessed by generating dose response curves from data obtained using various  
15 concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. In the control assay, the formation of complexes is quantitated in the absence of the test compound.

In certain embodiments, association between any two polypeptides in a complex or between the complex and a substrate polypeptide, may be detected by a variety of  
20 techniques, many of which are effectively described above. For instance, modulation in the formation of complexes can be quantitated using, for example, detectably labeled proteins (e.g., radiolabeled, fluorescently labeled, or enzymatically labeled), by immunoassay, or by chromatographic detection. Surface plasmon resonance systems, such as those available from Biacore International AB (Uppsala, Sweden), may also be  
25 used to detect protein-protein interaction.

In certain embodiments, one of the polypeptides of a complex can be immobilized to facilitate separation of the complex from uncomplexed forms of one of the polypeptides, as well as to accommodate automation of the assay. In an illustrative embodiment, a fusion protein can be provided which adds a domain that permits the  
30 protein to be bound to an insoluble matrix. For example, GST-NAK fusion protein can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with a potential

interacting protein (e.g., an  $^{35}\text{S}$ -labeled TNFR polypeptide), and the test compound are incubated under conditions conducive to complex formation. Following incubation, the beads are washed to remove any unbound interacting protein, and the matrix bead-bound radiolabel determined directly (e.g., beads placed in scintillant), or in the supernatant after the complexes are dissociated, e.g., when microtitre plate is used. Alternatively, after washing away unbound protein, the complexes can be dissociated from the matrix, separated by SDS-PAGE gel, and the level of interacting polypeptide found in the matrix-bound fraction quantitated from the gel using standard electrophoretic techniques.

10 In a further embodiment, compounds that bind to a complex may be identified by using an immobilized complex. In an illustrative embodiment, a fusion protein of a complex can be provided which adds a domain that permits the complex to be bound to an insoluble matrix. For example, a complex including a component of GST-TNF- $\alpha$  fusion protein can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with a potential labeled binding compound and incubated under conditions conducive to binding. Following incubation, the beads are washed to remove any unbound compound, and the matrix bead-bound label determined directly, or in the supernatant after the bound compound is dissociated.

20 In yet another embodiment, a two-hybrid assay (also referred to as an interaction trap assay) can be used for detecting the interaction of any two polypeptides in the complex (see also, U.S. Patent No. 5,283,317; Zervos et al., (1993) Cell 72:223-232; Madura et al., (1993) J. Biol. Chem. 268:12046-12054; Bartel et al., (1993) Biotechniques 14:920-924; and Iwabuchi et al., (1993) Oncogene 8:1693-1696), and for subsequently detecting test compounds which inhibit or potentiate binding of the proteins to one and other. This assay includes providing a host cell, for example, a yeast cell (preferred), a mammalian cell or a bacterial cell type. The host cell contains a reporter gene having a binding site for the DNA-binding domain of a transcriptional activator used in the bait protein, such that the reporter gene expresses a detectable gene product when the gene is transcriptionally activated. A first chimeric gene is provided which is capable of being expressed in the host cell, and encodes a "bait" fusion protein. A second chimeric gene is also provided which is capable of being

expressed in the host cell, and encodes the "fish" fusion protein. In one embodiment, both the first and the second chimeric genes are introduced into the host cell in the form of plasmids. Preferably, however, the first chimeric gene is present in a chromosome of the host cell and the second chimeric gene is introduced into the host cell as part of a  
5 plasmid.

Preferably, the DNA-binding domain of the first hybrid protein and the transcriptional activation domain of the second hybrid protein are derived from transcriptional activators having separable DNA-binding and transcriptional activation domains. For instance, these separate DNA-binding and transcriptional activation  
10 domains are known to be found in the yeast GAL4 protein, and are known to be found in the yeast GCN4 and ADR1 proteins. Many other proteins involved in transcription also have separable binding and transcriptional activation domains which make them useful for the present invention, and include, for example, the LexA and VP16 proteins. It will be understood that other (substantially) transcriptionally-inert DNA-binding  
15 domains may be used in the subject constructs; such as domains of ACE1, IclI, lac repressor, jun or fos. In another embodiment, the DNA-binding domain and the transcriptional activation domain may be from different proteins. The use of a LexA DNA binding domain provides certain advantages. For example, in yeast, the LexA moiety contains no activation function and has no known effect on transcription of  
20 yeast genes. In addition, use of LexA allows control over the sensitivity of the assay to the level of interaction (see, for example, the Brent et al., PCT publication WO94/10300).

In certain embodiments, the invention provides a two-hybrid assay to identify test compounds that inhibit or potentiate the stability of the complex. To illustrate, a  
25 first fusion protein (i.e., a "bait" protein) comprising a TNFR polypeptide and a second fusion protein (i.e., a "fish" protein) comprising a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2, are introduced in the host cell. Cells are subjected to conditions under which the bait and fish fusion proteins are expressed in sufficient quantity for the reporter gene to be activated. The interaction of  
30 the two fusion polypeptides of the complex results in a detectable signal produced by the expression of the reporter gene. Accordingly, the level of interaction between the two fusion proteins in the presence of a test compound and in the absence of the test

compound can be evaluated by detecting the level of expression of the reporter gene in each case. Various reporter constructs may be used in accord with the methods of the invention and include, for example, reporter genes which produce such detectable signals as selected from the group consisting of: an enzymatic signal, a fluorescent  
5 signal, a phosphorescent signal and drug resistance.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays of the present invention which are performed in cell-free systems, such as may be developed with purified or semi-  
10 purified proteins or with lysates, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of  
15 the drug on the molecular target as may be manifest in an alteration of binding affinity with other proteins or changes in enzymatic properties of the molecular target.

In certain embodiments, activities of a protein complex may include, without limitation, a protein complex formation, which may be assessed by immunoprecipitation and analysis of co-immunoprecipitated proteins or affinity  
20 purification and analysis of co-purified proteins. Fluorescence Resonance Energy Transfer (FRET)-based assays may also be used to determine complex formation. Fluorescent molecules having the proper emission and excitation spectra that are brought into close proximity with one another can exhibit FRET. The fluorescent molecules are chosen such that the emission spectrum of one of the molecules (the  
25 donor molecule) overlaps with the excitation spectrum of the other molecule (the acceptor molecule). The donor molecule is excited by light of appropriate intensity within the donor's excitation spectrum. The donor then emits the absorbed energy as fluorescent light. The fluorescent energy it produces is quenched by the acceptor molecule. FRET can be manifested as a reduction in the intensity of the fluorescent  
30 signal from the donor, reduction in the lifetime of its excited state, and/or re-emission of fluorescent light at the longer wavelengths (lower energies) characteristic of the

acceptor. When the fluorescent proteins physically separate, FRET effects are diminished or eliminated. (U.S. Patent No. 5,981,200).

For example, a cyan fluorescent protein is excited by light at roughly 425 - 450 nm wavelength and emits light in the range of 450 - 500 nm. Yellow fluorescent protein is excited by light at roughly 500 - 525 nm and emits light at 525 - 500 nm. If these two proteins are placed in solution, the cyan and yellow fluorescence may be separately visualized. However, if these two proteins are forced into close proximity with each other, the fluorescent properties will be altered by FRET. The bluish light emitted by CFP will be absorbed by YFP and re-emitted as yellow light. This means that when the proteins are stimulated with light at wavelength 450 nm, the cyan emitted light is greatly reduced and the yellow light, which is not normally stimulated at this wavelength, is greatly increased. FRET is typically monitored by measuring the spectrum of emitted light in response to stimulation with light in the excitation range of the donor and calculating a ratio between the donor-emitted light and the acceptor-emitted light. When the donor:acceptor emission ratio is high, FRET is not occurring and the two fluorescent proteins are not in close proximity. When the donor: acceptor emission ratio is low, FRET is occurring and the two fluorescent proteins are in close proximity. In this manner, the interaction between a first and second polypeptide may be measured.

The occurrence of FRET also causes the fluorescence lifetime of the donor fluorescent moiety to decrease. This change in fluorescence lifetime can be measured using a technique termed fluorescence lifetime imaging technology (FLIM) (Verveer et al., (2000) Science 290: 1567-1570; Squire et al., (1999) J. Microsc. 193: 36; Verveer et al., (2000) Biophys. J. 78: 2127). Global analysis techniques for analyzing FLIM data have been developed. These algorithms use the understanding that the donor fluorescent moiety exists in only a limited number of states each with a distinct fluorescence lifetime. Quantitative maps of each state can be generated on a pixel-by-pixel basis.

To perform FRET-based assays, a polypeptide of a complex (e.g., TNFR) and the interacting protein of interest (e.g., NAK) are both fluorescently labeled. Suitable fluorescent labels are, in view of this specification, well known in the art. Examples are provided below, but suitable fluorescent labels not specifically discussed are also

available to those of skill in the art. Fluorescent labeling may be accomplished by expressing a polypeptide as a fusion protein with a fluorescent protein, for example fluorescent proteins isolated from jellyfish, corals and other coelenterates. Exemplary fluorescent proteins include the many variants of the green fluorescent protein (GFP) of *Aequoria victoria*. Variants may be brighter, dimmer, or have different excitation and/or emission spectra. Certain variants are altered such that they no longer appear green, and may appear blue, cyan, yellow or red (termed BFP, CFP, YFP and RFP, respectively). Fluorescent proteins may be stably attached to polypeptides through a variety of covalent and noncovalent linkages, including, for example, peptide bonds (eg. expression as a fusion protein), chemical cross-linking and biotin-streptavidin coupling. For examples of fluorescent proteins, see U.S. Patents 5,625,048; 5,777,079; 6,066,476; 6,124,128; Prasher et al. (1992) *Gene*, 111:229-233; Heim et al. (1994) *Proc. Natl. Acad. Sci., USA*, 91:12501-04; Ward et al. (1982) *Photochem. Photobiol.*, 35:803-808 ; Levine et al. (1982) *Comp. Biochem. Physiol.*, 72B:77-85; Tersikh et al. (2000) *Science* 290: 1585-88.

FRET-based assays may be used in cell-based assays and in cell-free assays. FRET-based assays are amenable to high-throughput screening methods including Fluorescence Activated Cell Sorting and fluorescent scanning of microtiter arrays.

In general, where a screening assay is a binding assay (whether protein-protein binding, compound-protein binding, etc.), one or more of the molecules may be joined to a label, where the label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemiluminescers, enzymes, specific binding molecules, particles, e.g., magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc that are used to facilitate optimal protein-protein binding and/or reduce nonspecific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti- microbial compounds, etc. may be used. The mixture of components are added in any order that provides for the requisite binding.

Incubations are performed at any suitable temperature, typically between 4° and 40° C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening.

In certain embodiments, the invention provides complex-independent assays that are directed to a single polypeptide of the complex, such as TRCP1 or TRCP2. Such assays comprise identifying a test compound that is a candidate modulator of inflammation or apoptosis.

In an exemplary embodiment, a compound that bind to a TRCP1 or TRCP2 may be identified by using an immobilized TRCP1 or TRCP2 polypeptide. In an illustrative embodiment, a fusion protein of a TRCP1 or TRCP2 can be provided which adds a domain that permits the protein to be bound to an insoluble matrix. For example, a TRCP1 or TRCP2 fused with a GST protein can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with a potential labeled binding compound and incubated under conditions conducive to binding. Following incubation, the beads are washed to remove any unbound compound, and the matrix bead-bound label determined directly, or in the supernatant after the bound compound is dissociated.

In certain embodiments, a label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemilumescers, enzymes, specific binding molecules, particles, e.g., magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures. In certain embodiments, such methods comprise forming the mixture in vitro. In certain embodiments, such methods comprise cell-based assays by forming the mixture in vivo. In certain embodiments, the methods comprise contacting a cell that expresses a TRCP1 or TRCP2 polypeptide or a variant thereof with the test compound.

In certain embodiments, assays are based on cell-free systems, e.g., purified proteins or cell lysates, as well as cell-based assays which utilize intact cells. Simple binding assays can be used to detect compounds that interact with the TRCP1 or TRCP2 polypeptide. Compounds to be tested can be produced, for example, by



bacteria, yeast or other organisms (e.g., natural products), produced chemically (e.g., small molecules, including peptidomimetics), or produced recombinantly.

Optionally, test compounds identified from these assays may be used to treat TNF- $\alpha$  related diseases.

5

#### IX. Methods of Treatment

In certain embodiments, the present invention relates to methods for treating TNF- $\alpha$  related diseases using the protein complex. These methods are particularly aimed at therapeutic treatments of mammals, and more particularly, humans.

10 In certain aspects, a method for treating a TNF- $\alpha$ -related disease comprises administering an effective amount of an compound that inhibits the interaction of TNF- $\alpha$  or TNFR with a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

Preferably, such methods include administration of a small molecule, an  
15 antibody, or a peptide, as defined herein.

In certain aspects, a method of treating a TNF- $\alpha$ -related disease which includes an inflammatory or apoptotic component comprises administering an effective amount of a therapeutic composition that modulates TRCP1.

In certain aspects, a method of treating a TNF- $\alpha$ -related disease which includes  
20 an inflammatory or apoptotic component comprises administering an effective amount of a therapeutic composition that modulates TRCP2.

Gene therapy is also applicable in this regard with the use of nucleic acids encoding polypeptides of the protein complex, preferably nucleic acids encoding NAK, RasGAP3, TRCP1, and TRCP2 polypeptides.

25 As used herein, the term "TNF- $\alpha$  related disease refers to any disease that is mediated by TNF- $\alpha$  (and preferably through a TNFR). Exemplary TNF- $\alpha$  related diseases that may be treated in this way include diseases having an inflammatory or an apoptotic component. It is known that TNF- $\alpha$  is involved in apoptotic cell death, cellular proliferation, differentiation, inflammation, tumorigenesis, viral replication,  
30 viral infections, bacterial infections, parasitic infenctions, immune disorders, autoimmune pathologies, graft-versus-host pathologies. A few examples of TNF- $\alpha$  related disorders include cancer, rheumatoid arthritis, Chron's disease, asthma, septic

shock, irritable bowel disorder, haemorrhagic fever, and cachexia, the tissue wasting disorder often seen in cancer patients (see, for example, MacEwan DJ., (2002) *Cellular Signaling*, 14:477-492).

## 5 Exemplification

The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

10

### Example 1:

This exemplification describes the identification of proteins in the TNF- $\alpha$  receptor complex by using proteomic approaches as show in Figure 1.

Myelomonocytic leukemia cells (U937 cells) were incubated with or without  
15 FLAG-tagged TNF- $\alpha$ . Cells were then lysed, and the cell lysates were immunoprecipitated with an anti-FLAG antibody (M2) conjugated to the Sepharose beads. The immunoprecipitated complex was washed, and then eluted with FLAG peptides. To increase the eluted protein yields, the beads were further eluted with 8 M urea. The eluted proteins were separated by 4-12% SDS-PAGE gels and visualized by  
20 silver staining. Protein bands which showed increased level in the TNF- $\alpha$  treated cells compared to the non-treated cells, were excised from the gel. The gel slices were then digested with trypsin and the resultant tryptic peptides were separated on a microcapillary reversed phase column and eluted directly into a Finnigan LcQ ion trap mass spectrometer. Peptides were subjected to further fragmentation in the ion trap, and  
25 spectra were collected. The sequences of the spectra were obtained by a database searching using the SEQUEST software. Several proteins were identified in the TNF- $\alpha$  receptor complex by this method, for example TNF- $\alpha$ , TNF- $\alpha$  receptors, TRADD, TRAF2, TRAP2, NAK, RasGAP3, TRCP1, and TRCP2. Although TNF- $\alpha$  receptors are known to associate with such proteins as TRADD, TRAF2 or TRAP2 was known, the  
30 association of TNF- $\alpha$  receptors with NAK, RasGAP3, TRCP1, or TRCP2 was not described before. The presence of TRADD in the TNF- $\alpha$  receptor complex was further confirmed by Western Blotting with an anti-TRADD antibody.

Example 2:

This exemplification describes the ligand-induced binding of the TNFR1 with NAK, TRAF2, or TRADD in a time-dependent manner as shown in Figure 22.

5 Myelomonocytic leukemia cells (U937 cells) were incubated with FLAG-tagged TNF- $\alpha$  for 2, 5, 10, 20, or 30 minutes or left untreated. Cells were lysed by 0.5% Triton and the cell lysates were immunoprecipitated with an anti-FLAG antibody (M2) conjugated to the Sepharose beads. The immunoprecipitated complex was washed, eluted with protein sample buffer, and then resolved on 4-12% SDS-PAGE gels. The  
10 presence of NAK in the TNF- $\alpha$  receptor complex was detected by western blotting. Similarly, cells lysates were immunoprecipitated with an anti-TNFR1 antibody. The association of the TNF- $\alpha$  receptor with NAK, TRAF2, or TRADD was subsequently detected by western blotting with antibodies against NAK, TRAF2, or TRADD.

**15 Incorporation by Reference**

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

20

**Equivalents**

While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and  
25 the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

**Claims:**

1. An isolated, purified, or recombinant protein complex comprising:
  - (i) a tumor necrosis factor alpha (TNF- $\alpha$ ) polypeptide or a functional  
5 variant thereof;
  - (ii) a TNF- $\alpha$  receptor (TNFR) polypeptide or a functional variant thereof;  
and
  - (iii) at least one polypeptide selected from the group consisting of: NF- $\kappa$ B  
activating kinase (NAK), RasGAP3, TRCP1, TRCP2 and a  
10 functional variant thereof.
2. The complex of claim 1, wherein the TNFR polypeptide is a TNFR1 or TNFR2  
polypeptide.
- 15 3. The complex of claim 1, comprising a TNF- $\alpha$  polypeptide, a TNFR polypeptide  
and a NAK polypeptide.
4. The complex of claim 1, comprising a TNF- $\alpha$  polypeptide, a TNFR polypeptide  
and a RasGAP3 polypeptide.  
20
5. The complex of claim 1, comprising a TNF- $\alpha$  polypeptide, a TNFR polypeptide  
and a TRCP1 polypeptide.
6. The complex of claim 1, comprising a TNF- $\alpha$  polypeptide, a TNFR polypeptide  
and a TRCP2 polypeptide.  
25
7. The complex of claim 1, comprising a TNF- $\alpha$  polypeptide, a NAK polypeptide  
and a TNFR1 polypeptide.
- 30 8. The complex of any one of claims 1-7, further comprising at least one  
polypeptide selected from the group consisting of: TRADD, TRAF2, TRAP2  
and a functional variant thereof.

9. The complex of claim 8, comprising a TNF- $\alpha$  polypeptide, a NAK polypeptide, a TNFR1 polypeptide, a TRAF2 polypeptide and a TRADD polypeptide.
- 5 10. The complex of claim 8, comprising a TNF- $\alpha$  polypeptide, a TNFR polypeptide, a NAK polypeptide, a RasGAP3 polypeptide, a TRCP1 polypeptide, a TRCP2 polypeptide, a TRADD polypeptide, a TRAF2 polypeptide, and a TRAP2 polypeptide.
- 10 11. The complex of claim 1, wherein said TNF- $\alpha$  is a fusion protein.
12. The complex of claim 1, wherein said TNFR is a fusion protein.
13. The complex of claim 11 or 12, wherein said fusion protein comprises a domain  
15 that facilitates purification, isolation, or detection of said fusion protein.
14. The complex of claim 11 or 12, wherein said fusion protein comprises a domain selected from the group consisting of: affinity tags, radionucleotides, enzymes, and fluorophores.
- 20 15. The complex of claim 13, wherein said domain is selected from the group consisting of: polyhistidine, FLAG, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, and an immunoglobulin heavy chain constant region.
- 25 16. The complex of claim 13, wherein said domain is FLAG.
17. An isolated, purified, or recombinant protein complex comprising:  
(i) a TNF- $\alpha$  receptor (TNFR) polypeptide or a functional variant thereof;  
30 and

(ii) at least one polypeptide selected from the group consisting of: NF- $\kappa$ B activating kinase (NAK), RasGAP3, TRCP1, TRCP2 and a functional variant thereof.

- 5 18. The complex of claim 17, comprising a TNFR polypeptide and a NAK polypeptide.
19. The complex of claim 17, comprising a TNFR polypeptide and a RasGAP3 polypeptide.
- 10 20. The complex of claim 17, comprising a TNFR polypeptide and a TRCP1 polypeptide.
21. The complex of claim 17, comprising a TNFR polypeptide and a TRCP2 polypeptide.
- 15 22. The complex of claim 17, wherein said TNFR polypeptide is a TNFR1 polypeptide or a TNFR2 polypeptide.
- 20 23. The complex of any one of claims 17-22, further comprising at least one polypeptide selected from the group consisting of: TNF- $\alpha$ , TRADD, TRAF2, and TRAP2.
- 25 24. The complex of claim 23, comprising a TNF- $\alpha$  polypeptide, a TNFR polypeptide, a NAK polypeptide, a RasGAP3 polypeptide, a TRCP1 polypeptide, a TRCP2 polypeptide, a TRADD polypeptide, a TRAF2 polypeptide, and a TRAP2 polypeptide.
- 30 25. The complex of claim 17, wherein said TNFR polypeptide is a fusion protein.
26. The complex of claim 25, wherein said fusion protein comprises a domain that facilitates purification, isolation, or detection of said fusion protein.

27. The complex of claim 25, wherein said fusion protein comprises a domain selected from the group consisting of: affinity tags, radionucleotides, enzymes and fluorophores.
- 5
28. The complex of claim 26, wherein said domain is selected from the group consisting of: polyhistidine, FLAG, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, and an immunoglobulin heavy chain constant region.
- 10
29. The protein complex of any one of claims 1 and 17, wherein at least one protein in said complex is labeled.
30. The protein complex of claim 29, wherein said label is a detectable label.
- 15
31. The protein complex of claim 29, wherein said label is selected from the group consisting of: polyhistidine, FLAG, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, and an immunoglobulin heavy chain constant region.
- 20
32. An isolated protein complex comprising two or three polypeptides, the protein complex selected from the group consisting of:
- 25
- (i) a complex of a fragment of TNF- $\alpha$  polypeptide, a TNFR polypeptide and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
- (ii) a complex of a fragment of TNF- $\alpha$  polypeptide, a fragment of TNFR polypeptide and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
- 30
- (iii) a complex of TNF- $\alpha$  polypeptide, a TNFR polypeptide and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;

- (iv) a complex of TNF- $\alpha$  polypeptide, a fragment of TNFR polypeptide and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
- 5 (v) a complex of a fragment of TNF- $\alpha$  polypeptide, a TNFR polypeptide and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
- (vi) a complex of a fragment of TNF- $\alpha$  polypeptide, a fragment of a TNFR polypeptide and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
- 10 (vii) a complex of a fragment of TNFR polypeptide and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
- (viii) a complex of TNFR polypeptide and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and
- 15 TRCP2; and
- (ix) a complex of a fragment of TNFR polypeptide and a fragment of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.
- 20 33. A host cell comprising a first nucleic acid, a second nucleic acid and a third nucleic acid, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNF- $\alpha$  polypeptide, wherein the second nucleic acid comprises a recombinant nucleic acid encoding a TNFR polypeptide and wherein the third
- 25 nucleic acid comprises a recombinant nucleic acid encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.
- 30 34. The host cell of claim 33, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNF- $\alpha$  polypeptide, wherein the second nucleic acid comprises a recombinant nucleic acid encoding a TNFR1 polypeptide and wherein the third nucleic acid comprises a recombinant nucleic acid encoding a NAK polypeptide.



35. A host cell comprising a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNFR, and wherein the second nucleic acid comprises a recombinant nucleic acid encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.
36. The host cell of claim 35, wherein the first nucleic acid comprises a recombinant nucleic acid encoding a TNFR1 polypeptide and wherein the second nucleic acid comprises a recombinant nucleic acid encoding a NAK polypeptide.
37. An assay for identifying a test compound which inhibits or potentiates the stability of a complex, comprising:
- (a) forming a reaction mixture including:
    - (i) a TNF- $\alpha$  polypeptide;
    - (ii) a TNFR polypeptide;
    - (iii) at least one polypeptide selected from the group consisting of:  
NAK, RasGAP3, TRCP1, and TRCP2; and
    - (iv) a test compound; and
  - (b) detecting the presence of TNF- $\alpha$  or TNFR in the complex;
- wherein a change in the presence of TNF- $\alpha$  or TNFR in the complex in the presence of the test compound, relative to the presence of TNF- $\alpha$  or TNFR in the complex in the absence of the test compound, indicates that said test compound potentiates or inhibits the stability of said complex.
38. An assay for identifying a test compound which inhibits or potentiates the stability of a complex, comprising:
- (a) forming a reaction mixture including:
    - (i) a TNF- $\alpha$  polypeptide;
    - (ii) a TNFR polypeptide,
    - (iii) at least one polypeptide selected from the group consisting of:  
NAK, RasGAP3, TRCP1, and TRCP2; and

- (iv) a test compound; and
- (b) detecting the association between the TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
- 5 wherein a change in the association between TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the presence of the test compound, relative to the association between TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the absence of the test compound, indicates that said test
- 10 compound potentiates or inhibits the stability of said complex.
39. An assay for identifying a test compound which inhibits or potentiates the stability of a complex, comprising:
- (a) forming a reaction mixture including:
- 15 (i) a TNFR polypeptide;
- (ii) at least one polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2; and
- (iii) a test compound; and
- (b) detecting the association between the TNFR and a polypeptide selected
- 20 from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
- wherein a change in the association between TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the presence of the test compound, relative to the association between TNFR and a
- 25 polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2 in the absence of the test compound, indicates that said test compound potentiates or inhibits the stability of said complex.
40. A method for identifying a test compound which modulates activities of a
- 30 complex, comprising:
- (a) forming a protein complex comprising
- (i) a TNF- $\alpha$  polypeptide;

- (ii) a TNFR polypeptide,
- (iii) a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2; and
- (b) contacting the protein complex with a test compound, and
- 5 (c) determining the effect of the test compound for one or more activities selected from the group comprising (i) a change in the level of the protein complex, (ii) a change in the level of TNF- $\alpha$  or TNFR polypeptide in the protein complex, (iii) a change in the signaling enzymatic activity of the complex, or
- 10 (iv) a change in the interaction between the TNF- $\alpha$  or TNFR polypeptide and polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

41. A screening assay to identify compounds that inhibit or potentiate the stability of a complex, comprising
- 15 (i) providing a two-hybrid assay system including a first fusion protein comprising a TNFR polypeptide portion, and a second fusion protein comprising a portion of a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2, under conditions wherein said two hybrid assay is sensitive to interactions between the TNFR
  - 20 polypeptide and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;
  - (ii) measuring a level of interactions between said fusion proteins in the presence and in the absence of a test compound; and
  - (iii) comparing the level of interaction of said fusion proteins,
  - 25 wherein a decrease in the level of interaction is indicative of an compound that will inhibit the interaction between a TNFR polypeptide and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

42. An isolated antibody, or fragment thereof, specifically immunoreactive with an
- 30 epitope of a polypeptide selected from the group consisting of: TNF- $\alpha$ , TNFR, NAK, RasGAP3, TRCP1, and TRCP2, wherein said antibody disrupts

formation of an interaction between TNF- $\alpha$  and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.

- 5 43. An isolated antibody, or fragment thereof, specifically immunoreactive with an epitope of a polypeptide selected from the group consisting of: TNF- $\alpha$ , TNFR, NAK, RasGAP3, TRCP1, and TRCP2, wherein said antibody disrupts formation of an interaction between TNFR and a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.
- 10 44. A method for modulating, in a cell, a protein complex comprising at least a first protein and a second protein, wherein said first protein is TNFR, and wherein said second protein is selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2, said method comprising: administering to said cell a compound capable of modulating said protein complex.
- 15 45. The method of claim 44, wherein the protein complex further comprises TNF- $\alpha$ .
- 20 46. A method of producing a functional complex comprising:  
(i) transfecting a cell with a polynucleotide encoding a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2;  
(ii) contacting said cell with a TNF- $\alpha$  polypeptide;  
(iii) thereby forming a complex.
- 25 47. The method of claim 46, further comprising a TNFR polypeptide.
- 30 48. A method for treating a TNF- $\alpha$ -related disorder, by administering an effective amount of a compound that inhibits the interaction of TNF- $\alpha$  or TNFR with a polypeptide selected from the group consisting of: NAK, RasGAP3, TRCP1, and TRCP2.
49. The method of claim 48, wherein said compound is selected from the group consisting of: a small molecule, an antibody, and a peptide.

50. A method of identifying a test compound that is a candidate modulator of inflammation or apoptosis, the method comprising:

(i) forming a mixture comprising a TRCP1 polypeptide or a variant polypeptide thereof, and a test compound; and

(ii) measuring the interaction between the TRCP1 polypeptide or the variant and the test compound;

wherein a test compound that interacts with the TRCP1 polypeptide or functional variant is a candidate modulator of inflammation or apoptosis.

51. The method of claim 50, wherein (i) comprises forming the mixture in vitro.

52. The method of claim 50, wherein (i) comprises contacting a cell expressing a TRCP1 polypeptide or a variant thereof, with the test compound.

53. A method of identifying a test compound that is a candidate modulator of inflammation or apoptosis, the method comprising:

(i) forming a mixture comprising a TRCP2 polypeptide or a variant polypeptide thereof, and a test compound; and

(ii) measuring the interaction between the TRCP2 polypeptide or the variant and the test compound;

wherein a test compound that interacts with the TRCP2 polypeptide or functional variant is a candidate modulator of inflammation or apoptosis.


54. The method of claim 53, wherein (i) comprises forming the mixture in vitro.

55. The method of claim 53, wherein (i) comprises contacting a cell expressing a TRCP2 polypeptide or a variant thereof, with the test compound.

56. A method of treating a TNF- $\alpha$ -related disease which includes an inflammatory or apoptotic component, by administering an effective amount of a therapeutic composition that modulates TRCP1.

57. A method of treating a TNF- $\alpha$ -related disease which includes an inflammatory or apoptotic component, by administering an effective amount of a therapeutic composition that modulates TRCP2.

Figure 1.



**THIS PAGE BLANK (USPTO)**



Figure 2.

TNF $\alpha$

MSTESMIRDV ELAEEALPKK TGGPQGSRRCLFLSLSFLI  
VAGATTLECL LHFGVIGPQR EESPRDLSLISPLAQAVRSS  
SRTPSDKPVA HVVANPQAEGLQWLNR**RAN** **ALLANGVELR**  
**DNQLVVPSEG** **LYLIYSQVLF** **KGQGCPSTHV** **LLTHTISRIA**  
**VSYQTKVNLL** **SAIKSPCQRE** **TPEGAEAKPW** **YEPIYLGGVF**  
**QLEKGDRLSA** EINRPDYLDF AESGQVYFGI IAL

**THIS PAGE BLANK (USPTO)**

Figure 3.

DNA sequence of TNF $\alpha$ 

atgagcactgaaagcatgatccgggacgtggagctggccgagggagggcgtcccaagaaagacaggggggccccag  
ggctccaggcgggtgctgttctctcagcctcttctctctgacgtggcaggcggccaccacgctcttctgctgctgcaact  
ttggagtgatcggccccagagggaagggttccccagggacctctctataatcaggccctctggccccaggcagtcagatc  
atcttctcgaacccccgagtgacaaagcctgtagcccatgtgttagcaaacctcaaggctgaggggcagctccagtggtg  
aaccggccggggccaatgcccctctggccaatggcgtggagctgaggagataaacaggctgggtggccatcaggaggccct  
gtacctatctactcccaggctctcttcaaggggccaaggctggccccctccaccatgtgtctctcaccacacacatcagccc  
ggcatcggccgtctctaccagaccaaagggtcaacctctctctgtgccatcaaggagccccctggccaggaggagacccagagg  
gggctgaggggccaaggccctgggtatgagcccatctatctggggagggtcttccagctggagaaagggtggaccgactcagc  
gctgagatcaatcggcccgaactatctcgaacttggccgagcttgggcagggtctacttggggtatcattggccctgtgga

**THIS PAGE BLANK (USPTO)**

Figure 4.

## TNFR1

MGLSTVPDLL LPLVLELLV GIYPSGVIGL VPHLGDRER DSVCPQGYI  
HPQNNISICCT KCHKGTLYN DCPGPGQD TD **CRECESGFT** **ASENHLRHCL**  
SCSKCRKEMG QVEISSCTVD RDTVCGCRKN QYRHYWSENLFQCFNCSLCL  
NGTVHLSCQE **KQNTVCTCHA** **GFFLRENECV** SCSNCKKSLE CTKLCLPQIE  
NVKGTEDSGT TVLLPLVIF GLCLLSLFI GLMYRYQRWK SKLYSIVCGK  
STPEKEGELE GTTTKPLAPN PSFSPTPGFT PTLGFSVPVS STFTSSSTYT  
PGDCPNFAAP RREVAPPYQG ADPILATALA SDPIP NPLQK WEDSAHKPQS  
LDTDDPATLY AVVENVPPLR WKEFVRRRLGL SDHEIDRLEL QNGRCLREAO  
YSMLATWRRR TPRREATLEL LGRVLRDMDL LGCLEDIEEA LCGPAALPPA  
PSLLR.

**THIS PAGE BLANK (USPTO)**

Figure 5.

## DNA sequence of TNFR1

atggggcctctccaccgctggccctggacctgctgctggccgctggagctgcttggtgggaaataataccctcagggggtatttgggac  
tgggtccctaccctaggggacagggagagagatagtgtgtgtcccccaggaaaatatataccacctcaaaaataatcggatttggct  
gtaccaaagtggcacaaaaggaaacctacttgtacaaatgactgtccagggcccggggcagagataccggactgacagggagtgtagagagcgg  
gctcctcaccgcttcagaaaaaacacctcagacactgctcagctgctccaaatgccgaaaaggaaatgggtcaggtcaggtgagatctctt  
ctggcacagtggaccggggacaccgtgtgtgtgtgctgcagggaagaaaccagtagccggcattattggagtgaaacaccttttcagagtgttca  
attggagcctctgctcctaattgggaccgtgcacctctcctgcaggagaaacagaaacaccgtgtggcacctggccatggcaggtttcttctt  
aaaggaaaaacgagtggtgtctctgttagtaactgtaaagaaaagcctggagtgacaggaaagtgtgtccctaccccgagattggagaaatgttaa  
gggacagtggagctcagggcacccacagtgctgttggccctgggtcattttcttgggtcttggccttttatccctctcttctcattgggttaatgta  
tcgctaccaaaggtgggaagtccaaagctctactcattgttgggtgggaaatcgacacctgaaaaaaggaggggggagcttggaaaggaaacta  
ctactaaggccctggggcccaaaacccaaggctcagctccactccagggcttcaaccccccacccctgggtctcagtcccgccagttcca  
ccttcacctccagctccacctataccccgggtgactgttcccaactttggcggtctccccgcagagagagtggtggcacccacctatcagggggg  
gctggaaccccatcttggacaggccctcgctccgacctccgaccccatcccccaccccttcagaaagtggggagagagcgcacacaaagccca  
caggagccttagacactgtagaccccgagcgtgtacgcccgtgtgtgggagaaacgtgtccccgttggcgctggaaaggaaattcgtggcggg  
cgcttaggggctgagcgcgacacgagatcgatcggtggagctgtcagaaacggggcgctgtccctggcgagggcgcaatacagcatgct  
ggcgacctggagggcgcgacggcgcgagggccacggctggagctgtgtgggagcgctgtgtccggcgacatgggacctgctg  
gggtgctctgggaggacatcgaggaggcgcttggcgggccccggcctcccgccccggccttctcagatgta

**THIS PAGE BLANK (USPTO)**



Figure 6.

TNFR2

MAPVAVWAAL AVGLELWAAA HALPAQVAFT PYAPEPGSTC RLREYYDQTA  
QMCCSKCSPG QHAKVFCTKT SDTVCDSCED STYTQLWNWV PECLSCGSR  
**SSDQVETQAC** TREQNRICTC RPYWCALSK QEGCRLCAPL RKCRPGFGVA  
RPGTETSDVV CKPCAPGTFS NTTSSTDICR PHQICNVVAI PGNASMDAVC  
TSTSPTRSMA PGAVHLPQPV STRSQHTQPT PEPSTAPSTS FLPLMGPSPP  
AEGSTGDFAL PVGLIVGVTA LGLLIIGVNV CVIMTQVKKK PLCLQREAKV  
PHLPADKARG TQPEQQHLL ITAPSSSSSS LESSASALDR RAPTRNQPOA  
PGVEASGAGE ARASTGSSDS SPGGHGTQVN VTCIVNVCSS SDHSSQCSSQ  
ASSTMGDTDS SPSESPKDEQ VFESKEECAP RSQLETPETL LGSTEKPLP  
LGVPDAGMKP S.

**THIS PAGE BLANK (USPTO)**

Figure 7.

## DNA sequence of TNFR2

[illegible]

**THIS PAGE BLANK (USPTO)**

Figure 8.

TRADD

LAGVGTQAPP RRPGGEMAAG QNGHEEWVGS AYLFVSSLD KVVLSDAYAH  
PQOKVAVYRA LQAALAESGG SPDVLQMLKI HRSDPQLIVQ LRFECGRQPCG  
RFLRAYREGA LRAALQORSLA AALAQHSVPL QLELRAGAER LDALLADEER  
CLSCILAQQP DRLRDEELAE LEDALRNLC GSGARGGDGE VASAPLQPPV  
PSLSEVKPPP PPPPAQTFLF QGQPVVNRPL SLKDQQTFAR SVGLKWRKVG  
RSLQRCRAL RDPALDSLAY EYEREGLYEQ AFQLLRFFVQ AEGRRATLQR  
LVEALEENEL TSLAEDLLGL TDPNGGLA.

**THIS PAGE BLANK (USPTO)**

Figure 9.

DNA sequence of TRADD

ctggcggcggcgtggaaccacaggccccggccgaaggccgcccagagaggtgagatggcagctggcctgcaaaatggcgcacgaaggagtgc  
ggcggcagcagcgcataacctggttggaggagtcctcgcctggacaaagggtgctcctgtcggatggcctacggcgacacccccagcagcaga  
agggtggcaggtgtacagggtctctgacaggctgcccctggcagagaggcggcgaggccccggacggtgctgcaagatgctgaaagatc  
caccggcaggccccgacgctgcatcgtgacagctggcattctggcggcgcgacggccccctgtgtggccggcttctccggcgcctacccg  
cgaggcgggcgctgcccggcggcgtgacagaggaggccctggcggccggcctcggccagcactcgggtggccggcgaactggaggcc  
tgccggccccggccggcgtggacgcttttggcggcgacggaggcggcgtgtttgagttgcatcctagccccagcaggcccc  
ggaccggctccgggtatgaaaggaaactggctgagcgtgaggatgctgctggcgaatatctgaaagtggcggctcggggggccccgggggtgg  
cgacggggagggtcggcttcggcccccttgcaggccccccgggtggccctctctgtctggagggtgaaaggccccggccggccggccac  
ctggccagacttttctgtccagggtcaggcctgtagtgaaatggggcgtgagcctgaaaggagaccaacagacggttcggcggcgc  
tctgtgggtctcaaatggcgcaagggtggggcggtcactgacggcgagggtggccggcgctggcggcgctggcggggacccggcgctggactc  
gctggcgcctacgaggtacgagcgcgaggggactgtacgagcggccttccaggctgctggcggcgctgctggcagggccccggaggggcc  
ggccggccacggctgacggcggcctgggtggaggggcactcggaggagagactcaccaggcctggggcaggaggactgtggcggcctgg  
accgatcccaatggcgggcctggccctag

**THIS PAGE BLANK (USPTO)**



Figure 10.

WO 2004/01

PCT/US2003/024340

10/523328

TRAF2  
(TNF receptor-associated protein 2)

MAAASVTPPG SLELLQPGFS KTLGKLEA **KYLC****SACRNV** **LRPFQAQCG**  
**HRYCSFCLAS** ILSSGPQNCA ACVHEGIYEE GISILESSA FPDNAARREV  
ESLPAVCPSD GCTWKGTLEK YESCHEGRCP LMLTÉCPACK GLVRLGEKER  
HLEHECPERS LSCRHCRAPC CGADVKAHHE VCPK**FPLTCD** **GCGKKKIPRE**  
KFQDHVKTCG KCRVPCRFAH IGCLÉTVEGE KQQEHEVQWL REHLAMLLSS  
VLEAKPLLGD QSHAGSELLQ RCE**SLEKKTA** **TFENIVCVLN** **REVERVAMTA**  
**EACSRQHRLD** QDKIEALSSK VQQLERSIGL **KDLAMADLEQ** **KVRPFQAQCG**  
HRYCSFCLAS ILRKLQEAVA **GRIPAIFSPA** **FYTSRYGYKM** CLRIYLN**GDG**  
TGRGTHLSLF FVVMKGPNDALLRWPFNQKV **TLMLLDQNNR** EHVIDAFRPD  
VTSSSFQRPV NDMNIASGCP LFCPVSKMEA  
KNSYVRDDAI FIKAIVDLTG L

DT12 Rec'd PCT/PTO 01 FEB 2005

**THIS PAGE BLANK (USPTO)**

Figure 11.

## DNA sequence of TRAF2

atggctgagctagcgtagcccccccctggctccctggagttgctacagccccggcttctccaagacccctcctggggaccaa  
gctggaagccaaagtacctgtgctccgctgcagaaacgtctccgcaggccccctccaggcgagtggtggccaccgggtact  
gctccttctgcctggccagcatcctcagctctgggctcagaactgtgctgcctgtgttcacgagggcataatgaagaa  
ggcatttctatttagaaagcagttcggcctccagataatgctgccgcaggaggtggagagcctgccggcctgtg  
tcccagtgatggatgcacctggaagggaacccctgaaagaatacagagagctgccacgaaggccgctgcccgctcatgctga  
ccgaatgtcccgcgtgtaaggcctggtccgccttggtagaaaggagcgccacctggagcacgagtgcccggagagaagc  
ctgagctgccggcattgccgggcaacctgctgcggagcagacgtgaaggcgccaccacgaggtctgccccaaagtccccctt  
aacttgtgacggctgcgggcaagaagaagatccccggggagaagtctcaggaccacgctcaagacttgtggcaagtgtcgag  
tcccttgagattccacgccatcggtgctcgagacggtagaggtgagaaacagcaggagcacgaggtgcagtggtggtg  
cggagcaacctggccatgctactgagctcggtgctggaggcaaacccccctcttgggagaccagagccacgcggtgcaga  
gctcctgcagaggtgcgagagcctggagaagaagacggccacttttgagaacattgtctgcgtcctgaaccgggaggtgg  
agagggtggccatgactgccgagcctgcagccggcagcacccggctggaccacaagattgaagccctgagtagcaag  
gtgcagcagctggagaggagcatggcctcaaggacctggcgatggctgacttggagcagaaggtcaggccccctccaggc  
gcagtgtggccaccggtactgctccttctgcctggccagcatcctcaggaagctccaggaagctgtggctggccgcatac  
ccgccatcttctcccagccttctacaccagcaggtacgggtacaaagatgtgtcgtgtatctacctgaacggcgacggc  
accgggaggaacaacacctgtccctcttcttgggtgatgaaggggcccgaaatgacgccccctgctgcggtggccccctcaa  
ccagaagggtgaccttaatgctgctcgaccagaataaacgggagcacgtgattgacgccccctcaggccccgacgtgacttcat  
cctcttttcagaggccagtcacacgacatgaacatcgcaaggcgtgccccctcttctgccccctctccaagatggaggca  
aagaattcctacgtgcgggacgatgccatcttcatcaaggccattgtggacctgacagggtctctaa

DT12 Rec'd PCT/PTO 01 FEB 2005

**THIS PAGE BLANK (USPTO)**

Figure 12.

## TRAP2

MEEGRDKAP VQQQSPAAA PGGDEKPSG KERRDAGDKD KEQELSEEDK QLQDELEMLA  
 ERLGEKDTSL YRPALIELRR QIRSSTTSMT SVPKPLKFLR PHYGKLKEIY ENMAPGENKR  
 FAADIISVLA MTMSGERECL KYR**LVGSQEE** **LASWGHEYVR** HLAGEVAKEW QELDDAEKVQ  
 REPLTLVKE IVPYNMAHNA EHEACDLLME IEQVDMLEKD IDENAYAKVC LYLTSCVNYV  
 PEPENSALLR CALGVFRKFS RFPEALRLAL MLNDMELVED IFTSCKDVVV QKQMAFMLGR  
 HGVFLELSED VEEYEDLTEI MSNVQLNSNF LALARELDIM EPKVPDDIYK THLENNRFGG  
 SGSQVDSARM **NLASSFVNGF** **VNAAFGQDKL** LTDDGNKWLY KNKDHGMLSA AASLAMILLW  
 DVDGGLTQID KYLYSSEDIY KSGALLACGI VNSGVRNECD PALALLSDYV LHNSNTMRLG  
 SIFGLGLAYA GSN**REDVLT**L **LLPVMGDSKS** SMEVAGVTAL ACGMIAVGSC NGDVTSTILQ  
 TIMEKSETEL KDTYARWLPL GLGLNHLGKG EAIEAILAAL EVVSEPFERSF ANTLVDVCAY  
 AGSGNVILKVQ QLLHICSEHF DSKEKEEDKD KKEKKDKKK EAPADMGAHQ GVAVLGIALI  
 AMGEEIGAEM ALRTFGHLLR YGEPTLRR**AV** **PLALALISVS** **NPRLNILDTL** SKFSDADPE  
 VSYNSIFAMG MVSGGTNNAR LAAMLRLQ**LAQ** YHAK**DPNNLF** **MVR**LAQGLTH LGKGTTLTCLP  
 YHSDRQLMSQ VAVAGLLTVL VSFLDVRNII LGKSHYVLYG LVAAMQ**PRML** **VTFDEELRPL**  
**PVSVRVGQAV** **DVVGQAGKPK** TITGFQTHTT PVLLAHGERA ELATEEFLPV TPILEGFVIL  
 RKNPNYDL.

**THIS PAGE BLANK (USPTO)**

Figure 13.

## DNA sequence of TRAP2

[illegible]

**THIS PAGE BLANK (USPTO)**



Figure 14.

## NAK/TBK/T2K

1	MQSTSNHLWL	LSDILGQGAT	ANVFRGRHKK	<b>TGDLFAIKVF</b>	<b>NNISFLRPVD</b>
51	<b>VQMR</b> EFEVLK	KLNHKNIVKL	<b>FAIEEETTTR</b>	HKVLIMEFCP	CGSLYTVLEE
101	PSNAYGLPES	EFLIVLRDVV	<b>GGMNH</b> LRENG	IVHRDIKPGN	IMRVIGEDGQ
151	<b>SVYK</b> LTDFGA	ARELEDDQF	VSLYGTEEYL	HPDMYERAVL	RKDHQKKYGA
201	TVDLWSIGVT	FYHAATGSLP	FRPFEGRPRN	KEVMYKIITG	KPSGAISGVQ
251	KAENGPIDWS	GMPVSCSLS	<b>RGLQVLLTPV</b>	<b>LANILEADQE</b>	<b>KCWGFDQFFA</b>
301	ETSDILHRMV	IHVFSLQQMT	AHKIYIHSYN	TATIFHELVY	KQTKIISNNQ
351	<b>ELIYEGRRLV</b>	<b>LEPGRLAQHF</b>	<b>PKTTEENPIF</b>	<b>VVSREPLNTI</b>	<b>GLIYEKISLP</b>
401	KVHPRYDLDG	DASMAKAITG	<b>VVCYACRIAS</b>	<b>TLLLYQEIMR</b>	KGIRWLIELI
451	KDDYNETVHK	KTEVVITLDF	CIRNIEKTVK	<b>VYEKLMKINL</b>	<b>EAAELGEISD</b>
501	<b>IHTKLLRLSS</b>	<b>SQGTIETSLQ</b>	<b>DIDSRLSPGG</b>	<b>SLADAWAHQE</b>	<b>GTHPKDRNVE</b>
551	KLQVLLNCMT	EIYYQFKKDK	AERRLAYNEE	QIHKFDKQKL	YYHATKAMTH
601	FTDECVKKYE	AFLNKSEEWI	RKMLHLRKQL	LSLTNQCEDI	EEEVSKYQEY
651	TNELQETLPQ	KMFTASSGIK	HTMTPIYPSS	NTLVEMTLGM	KKLKEEMEGV
701	<b>VKELAENNH</b> I	<b>LERFGSLTMD</b>	<b>GGLRNVDC</b> IL		

**THIS PAGE BLANK (USPTO)**

Figure 15. DNA sequence of NAK

atgcagagcactctaatacatctgtggctttatctgatatcttagccaggagctactgcaaatgtctttcgtggaaacataaagaaaactggtga  
tttattgctatcaaaagtatttaataacataagcttccttcgtccagtggtgtaaatgagagaatttgaagtgttgaaaaaactcaatcacaaaaat  
attgtcaaatatttgcctattgaaggagagacaacaagacataaagtaactattattggaatttgcacgtggtggaatgaatcatctacgagaaatggtatagt  
gaaccttctaataatgcctatggactaccagaatctgaattctaattgttttgcgagatgtggtggtggaatgaatcatctacgagaaatggtatagt  
gcaccgtgatatcaagccaggaaatatcatgcgtgttatagggggaagatggacagctctgtgtacaaaactcacagatttggcagctagagaat  
tagaaagatgatgagcagtttggttctctgtatggcacagaaataatttgcacctgatatgtatgagagcagtgctaagaaaaagatcatcaga  
agaaatatggagcaacagtttgatcttgggagcattggggttaacattttaccatgcagctactggatcactgccatttagaccttgaaggccctc  
gtaggaataaagaaagtatgtataaaataattacagggaaaagcccttctgggtgcaatatctggagtacagaaaagcagaaaatggaccaattgactg  
gagtgagacatgcctgtttcttcagtccttctcgggtcttcagggttctacttaccctgttcttgcacaaacatccttgaagcagatcagggaaaagt  
gttgggggttttgaccagtttttgcagaaaactagtatatacttccaccgaatggtaattcatgttttttgcctacaacaaatgacagctcataagattat  
attcatagctataatactgctactatatattcatgaactggtatataaacaacaaaatttctcaaatcaagaacttatctacgaaaggccgacgc  
ttagtcttagaacctggaaaggctggcacaacatttccctaaaactactgaggaaaacccctatatattttagtaagccgggaacctctgaataccata  
ggattaataatgaaaaaatttccctcctaaagtagatccacgttatgatttagacggggatgctagcatgggctaagggcaataacaggggttgtg  
tgttatgcctgcagaattgccagtaaccttactgctttatcaggaattaatgcgaaaggggatagcgtgattgaattaaagatgattacaa  
tgaaactgttcacaaaaagacagaaagttgtgatacattggatttctgtatcagaaaaacattgaaaaaacctgtgaaagtatatgaaaaagtgtgatgaa  
gatcaacctgggaaggcgagagtaggtgaaatttcagacatacacaccaaattgttgagacttccagttctcagggcaacaatagaaaaaccagt  
cttcaggatatcgacagcagattatctcaggtggatcacatggcagacgcatgggcacatcaagaaggcactcatccggaaagacagaaaatgta  
gaaaaactacaagtcctgtttaaattgcatgacagagatttactatcagttcaaaaaagacaaaagcagaaacgtagatttagcttataatgaagaaca  
aatccacaaattgataaagcaaaaactgtattaccatgccacaaaaggctatgacgcactttacagatgaatgtgttaaaaaagtatgagcatttttg  
aataagtcagaagaatggataaagaaagatgcttcatctcttaggaaaacagttattatcgtgactaatcagtttttgatattgaagaaagaaagtataa  
aatataagaataatactaatgagttacaagaaaactctgcctcagaaaatgttttacagcttccagtggaatcaaacataccatgaccccaattatcc  
aagttctaacacattagtaaaatgactcttggtatgaagaaattaaaggagagatggaaagggtgttaagaaactgtgaaaaataaccaca  
ttttagaaaagggttggctctttaaccatggatgggtggcccttcgcaacgttgactgtctttag

**THIS PAGE BLANK (USPTO)**

Figure 16.

## RasGAP3

MAVEDEGLRV FQSVKIKIGE AKNLPSYGP SKMRDCYCTV NLDQEEVFRT KIVEKSLCPF  
 YGEDFYCEIP RSFRHLSFYI FDRDVFRDSD IIGKVAIQKE DLQKYHNRDT WFQLQHVDDAD  
 SEVQGVHLE LRLSEVITDT GVVCHKLATR IVECCGLPIV NGQCDPYATV TLAGPFRSEA  
 KKTGVKRKTN NPQFDEVFYE EVTRPCSYSK KSHFDFEED VDKLEIRVDL WNASNLKFGD  
**EFLGELRIPL** KVLRSQSSYE AWYFLQPRDN GSKSLKPDDL GSLRLNVVYT **EDHVFSSDYY**  
**SPLRDL**LLKS ADVEPVASASA AHILGEVCRE KQEAAPLVLR LFLHYGRVVP **FISAIASAEV**  
**KRTQDPNTIF** RGNSLASKCI DETMKLAGMH YLHVTLKPAL EEICQSHKPC EIDPVLKLDG  
 ENLENNMENL RQYVDRVFHA ITESGVSCPT VMCDIFFSLR EAAAKRFQDD PDVRYTAVSS  
**FIFLRFFAPA** ILSPNLFQLT PHHTDPQTSR TLTLLISKTVQ **TLGSLSKSKS** ASFKESYMAT  
 FYEFFNEQKY ADAVKNFIDL **ISSGRRDPK** LYSIPIENIL AVEKLEESF KMKNMFQVIQ **PERALYIQAN**  
 RWERLTNHEF TYHKSKGDQP KRLTVYHPSA YLSGHWLCCR APSDSAPGCS PCTGGLPANI  
 NCVEAKDWID ILTKVSQCNCQ MSKLEKMQEA CGSKSVYDGP EQEEYSTFVI DDPQETYKTL  
 QLDIDGDRET ERIYSLFNLY KFKKTKYGSQ EHPIGDKSFQ NYIRQQSETS THSI.

DT12 Rec'd PCT/PTO 01 FEB 2005

**THIS PAGE BLANK (USPTO)**

Figure 17.

## RasGAP3 DNA sequence

[illegible]

**THIS PAGE BLANK (USPTO)**



Figure 18.

## TRCP1 (KIAA0143)

MPTRVCCCS ALRPRYKRLV DNIPEDEPKD GLVKTDMEKL TFYAVSAPEK **LDRIGSYLAE**  
 RLSRDVVRHR SGYVLIAMEA LDQLLMACHS QSIKPFVESF LHMVAKLLES GEPKLQVLGT  
 NSFVKFANIE **EDTPSYHRRY** DFFVSRFSAM CHSCHSDPEI RTEIRIAGIR GIQGVVRKTV  
 NDELRTIWE PQHMDKIVPS LLENMQKIEE VDSRIGPPSS PSATDKEENP AVLAENCFRE  
 LLGRATEGNM NNAVRPVFAH LDHHKLWDPN EFAVHCFKII MYSIQAQYSH HVIQEIILGHL  
 DARKKDAPRV **RAGIIQVLL** **AVAI****AKGSI** **GPTVLEVFNT** **LLKHLRLSVE** FEANDLQGGS  
 VGSVNLNTSS KDNDEKIVQN AIIQTIGFFG SNLPDYQRSE IMMFMGKVP **VFGTSTHTLD**  
**ISQLGDLGTR** RIQIMLLRSL LMVTSGYKAK TIVTALPGSF LDPLLSPSLM EDYELRQLVL  
 EVMHNLMDRH DNRAKLRGIR IIPDVADLKI KREKICRQDT SFMKKNGQQL YRHIYLGCKE  
 EDNVQKNYEL LYTSLALITI ELANEEVVID LIRLAIALQD SAIINEDNLP MFHRCGIMAL  
 VAAYLNEVSQ MIAVPAPFCQH VSKVIEIRTM EAPYFLPEHI FRDKCMLPKS LEKHEKDIYF  
 LTNK**IAESLG** **SGYSVERLS** VPYVPQVTDE DRLSRRKSIV DTVSIQVDIL SNNVPSDDV  
 SNTTEITFEA LKKAIDTSGM EEQEKERRRL VIEKFQKAPF EEIAAQCESK ANLLHDLRLAQ  
 ILELTIRPPP SPSGTLTITS GHAQYQSVPV YEMKFPDLCV Y

**THIS PAGE BLANK (USPTO)**

Figure 19.

[illegible]

**THIS PAGE BLANK (USPTO)**

Figure 20.

TRCP2 (similar to FLJ20758)

MAVSAVRWL GLRSRLGQPL TGRRAGLCEQ ARSCRFYSGS ATLSKVEGTD VTGIEEVVIP  
KKKTWDKVAV LQALASTVNR DTTAVPYVFQ DDPYIMPASS LESRSFLLAK KSGENVAKFI  
INSYPKYFQK DIAEPHIPCL MPEYFEPQIK DISEAALKER IELRKVKASV DMFDQLLQAG  
TTVSLETTNS LLDLLCYIGD QEPSTDYHFQ QTGQSEALEE ENDETSRRKA GHQFGVTWRA  
KNNAEIRIFSL MPEKNEHSYC TMIRGMVKHR AYEQAALNLYT ELLNNRLHAD VYTENALIEA  
TVCAINEKFE EKWSKILELL RHMVAQKVKP NLQTFENTILK CLRRFHVFAF **SPALQVLREM**  
KAIGIEPSLA TYHHIIRLFD **QPGDPLKRSS** **FIIDIMNEL** **MGRFSPKDP** DDDKFFQSAM  
SICSSLRDLE LAYQVHGLLK TGDNWKFIGP DQHRNFYYSK FFDLILCLMEQ IDVTILKWYED  
LIPSAFFPHS QTMIHLLQAL DVANRLEVIP KIWKDSKEYG HFFRSDLREE **ILMLMARDKH**  
PPELQVAFAD CAADIKSAYE **SQPIRQTAQD** **WPATSLNCIA** **ILFLRAGRTQ** EAWKMLGLER  
KHNKIPRSEL **LNELMDSAKV** SNSPSQAIEV VELASAFSLP ICEGLTQVRM **SDFAINQEQK**  
EALSNLTALT SDSDTDSSD SDSDTSEGK

**THIS PAGE BLANK (USPTO)**


Figure 21. DNA sequence of TRCP2 (similar to FLJ20758)

atggcggtgtatctgctgttcgctggcgctggcgcccgagcagcgcttgcccgagcccgctgacggcgctggcggttgggtgaac  
aggcacgcagctgcagattttattctgtagtgcaacctctcaagggtgaaggaaactgatgtaacagggttggaagtagtaattcc  
aaaaaagaaaactgggataaagtagccgttcttcaggcactgcatccacagtaaacagggtgataccacagctgtgcttattgtttcaa  
gatgaccttacccttatgccagcatcatctttggaaatctcgttcatctttactggcaaaagaaatccggggagaaatgtggccaaagtattatttaa  
ttcataccccaataatttcagaaggagacatagctgaacctcatataccgtgtttaatgcctgagtactttgaacctcagatcaaaagacataaag  
tgaagccgccctgaaaggaaacgaattgagctcagaaaaagtcataagccctctgtggacatgtttgatcagcttttgcaagcaggaaaccactgt  
gtctcttgaacaacaataatagtccttggatttattgtttactatgtgtgaccaggagccctcaactgattaccatttcaacaaactgggacag  
tcagaagcattggaaaggaaaaatgatgagacatctagaggaaaaagctgtgcatcagtttgaggttacatggcgaggcaaaaaaacaaacg  
ctgagagaaatctttcttaatgccagagaaaaatgaacattcttattgcacaatgatccgggaatgggtgaagcaccgagcttatgagca  
ggcattaaactgtacactgagttactaaacaacagactccatgctgatgtatacacatttaatgcatgtgattgaaggcaacagtatgtgcgat  
aaatgagaaaattggagaaaaatggagtaaaatactggagctgtaagacacatggttgcacagaagggtgaaccaaactcttcagacttt  
taataccattctgaaatgtctccgaagatttcatgtgtttgcaagatcgccagccttacagggtttacgtgaaatggaagccattggaaataga  
accctcgcttgcaacatatcaccatatatttcgcctgtttgatcaacctggagaccctttaagagatccttcattcatatttatataatga  
atgaattaatgggaaaggagattttctc aaaggaccgggatgatgataagtttttcagtcagccatgagcatatgctcatctctcagagatc  
tagaaacttgccctaccaagtacatggccctttaaaaccggagacaaactggaaattcattggaccctgatcaacatcgtaatttctattattcca  
agttcttcgatttgatttgtaatggaacaaatgatgttaccttgaaagggtgatgaggaccctgatacccttcagcctacttccccactcccaa  
acaatgatacatcttctccaaaggcattggatgtggccaatcggtagaaagtattcctaaatttgaaaattggaagatagtaaagaatatggtcatac  
tttccgcagtgacctgagagaaagagatccigtatgctcatgagcaaggacagactgctcaggttgccagcctctcactcactgtgactgtg  
ctgctgataatcaaatctgcgtatgaaagcccaaccatcagacagactgctcaggttgccagccacctctcactcactgatatagctatcct  
cttttaaggctggagaaactcaggaagccctggaaaaatgttggcgcttttcaggaagcataaagattcctagaagtgagtgctgaat  
gagcttaaggagagcaaaagtgtctaacagcccttccagggccattgaaagttagagctggcgaagtgccttcagcttaccctattgtg  
aggcgctcaccagagagtaatgagtgattttgcaatcaaccaggaacaaaaggaaagccctaaagtaatacttaactgcatggaccagtgac  
agtgtactgacagcagtgacagcgacagtgacacagtggaaggcaaatga

**THIS PAGE BLANK (USPTO)**



Figure 22.

TNF $\alpha$ -dependent recruitment of NAK on TNFR1

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**BEST AVAILABLE COPY**